<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Transl Med</journal-id><journal-id journal-id-type="iso-abbrev">J Transl Med</journal-id><journal-title-group><journal-title>Journal of Translational Medicine</journal-title></journal-title-group><issn pub-type="epub">1479-5876</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7913442</article-id><article-id pub-id-type="publisher-id">2754</article-id><article-id pub-id-type="doi">10.1186/s12967-021-02754-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>FOXO1 mitigates the SMAD3/FOXL2<sup>C134W</sup> transcriptomic effect in a model of human adult granulosa cell tumor</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5725-9214</contrib-id><name><surname>Secchi</surname><given-names>Christian</given-names></name><address><email>chsecchi@health.ucsd.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Benaglio</surname><given-names>Paola</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mulas</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Belli</surname><given-names>Martina</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Stupack</surname><given-names>Dwayne</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shimasaki</surname><given-names>Shunichi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.266100.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 4242</institution-id><institution>Department of Obstetrics, Gynecology, and Reproductive Sciences, </institution><institution>University of California, San Diego School of Medicine, </institution></institution-wrap>9500 Gilman Drive, La Jolla, CA 92093 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.266100.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 4242</institution-id><institution>Department of Pediatrics, </institution><institution>University of California San Diego, School of Medicine, </institution></institution-wrap>La Jolla, CA USA </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>2</month><year>2021</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>2</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>19</volume><elocation-id>90</elocation-id><history><date date-type="received"><day>21</day><month>12</month><year>2020</year></date><date date-type="accepted"><day>16</day><month>2</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2021</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Adult granulosa cell tumor (aGCT) is a rare type of stromal cell malignant cancer of the ovary characterized by elevated estrogen levels. aGCTs ubiquitously harbor a somatic mutation in <italic>FOXL2</italic> gene, Cys134Trp (c.402C&#x02009;&#x0003c;&#x02009;G); however, the general molecular effect of this mutation and its putative pathogenic role in aGCT tumorigenesis is not completely understood. We previously studied the role of FOXL2<sup>C134W</sup>, its partner SMAD3 and its antagonist FOXO1 in cellular models of aGCT.</p></sec><sec><title>Methods</title><p id="Par2">In this work, seeking more comprehensive profiling of FOXL2<sup>C134W</sup> transcriptomic effects, we performed an RNA-seq analysis comparing the effect of FOXL2<sup>WT</sup>/SMAD3 and FOXL2<sup>C134W</sup>/SMAD3 overexpression in an established human GC line (HGrC1), which is not luteinized, and bears normal alleles of <italic>FOXL2</italic>.</p></sec><sec><title>Results</title><p id="Par3">Our data shows that FOXL2<sup>C134W</sup>/SMAD3 overexpression alters the expression of 717 genes. These genes include known and novel FOXL2 targets (<italic>TGFB2</italic>, <italic>SMARCA4</italic>, <italic>HSPG2</italic>, <italic>MKI67</italic>, <italic>NFKBIA</italic>) and are enriched for neoplastic pathways (Proteoglycans in Cancer, Chromatin remodeling, Apoptosis, Tissue Morphogenesis, Tyrosine Kinase Receptors). We additionally expressed the FOXL2 antagonistic Forkhead protein, FOXO1. Surprisingly, overexpression of FOXO1 mitigated 40% of the altered genome-wide effects specifically related to FOXL2<sup>C134W</sup>, suggesting it can be a new target for aGCT treatment.</p></sec><sec><title>Conclusions</title><p id="Par4">Our transcriptomic data provide novel insights into potential genes (FOXO1 regulated) that could be used as biomarkers of efficacy in aGCT patients.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>RNA-seq</kwd><kwd>FOXL2</kwd><kwd>SMAD3</kwd><kwd>FOXO1</kwd><kwd>Adult granulosa cell tumor</kwd><kwd>HGrC1</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R01CA244182</award-id><principal-award-recipient><name><surname>Shimasaki</surname><given-names>Shunichi</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009633</institution-id><institution>Eunice Kennedy Shriver National Institute of Child Health and Human Development</institution></institution-wrap></funding-source><award-id>P50HD012303</award-id><principal-award-recipient><name><surname>Shimasaki</surname><given-names>Shunichi</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007911</institution-id><institution>University of California, San Diego</institution></institution-wrap></funding-source><award-id>RPR378B</award-id><principal-award-recipient><name><surname>Shimasaki</surname><given-names>Shunichi</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par17">Granulosa cell tumors (GCTs) are a rare form of stromal cell malignant cancer accounting for one in twenty cases of ovarian cancer. GCTs can occur as either adult or juvenile subtypes [<xref ref-type="bibr" rid="CR1">1</xref>]. Commonly the adult form of GCTs is diagnosed at an early stage and can be treated surgically. However, these tumors often recur, and are predominantly fatal in case of recurrence [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Current research is focused on discovering new molecular markers to predict the progression of aGCTs. Established cancer markers have no prognostic significance for this type of tumor. Indeed, while many types of tumors show prognostic induction of oncogenes or inactivation of tumor suppressor genes, aGCTs reveal a modestly impacted genome. The immunohistochemical evaluation of different oncogenes and tumor suppressors (<italic>e.g.,</italic> MYC, CDKN1A, ERBB2 and TP53) failed to detect a correlation with patient outcome [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par18">More than 400 tumors from aGCT patients of diverse ethnicities [<xref ref-type="bibr" rid="CR7">7</xref>] showed one single mutation in the Forkhead box L2 transcription factor gene FOXL2: Cys134Trp (c.402C&#x02009;&#x0003c;&#x02009;G) [<xref ref-type="bibr" rid="CR8">8</xref>], however its role in the onset of aGCTs is still matter of investigation [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. The mutation is not present in other cancers. FOXL2 is expressed in the ovarian granulosa cells (GCs) and plays a key role during the development of female reproduction system and in its maintenance [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. Potential FOXL2 targets revealed by ChIP and RT-PCR implicated its involvement in follicular and craniofacial development [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. It has been also shown that FOXL2 affects collagen synthesis [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Nicol et al<italic>.</italic> carried out the first ChIP-seq on mouse FOXL2<sup>WT</sup> in order to find its direct target [<xref ref-type="bibr" rid="CR23">23</xref>]. In 2011, Benayoun et al. demonstrated that FOXL2 plays a key role in the homeostasis of GCs and its failure leads to ovarian aging and tumorigenesis [<xref ref-type="bibr" rid="CR24">24</xref>]. This mutation hyperactivates aromatase and downregulates GC apoptosis pathways [<xref ref-type="bibr" rid="CR10">10</xref>]. Whole transcriptome analysis of 10 aGCT patient samples showed that the FOXL2<sup>C134W</sup> acts as a hypomorphic mutant on the normally FOXL2<sup>WT</sup> activated genes [<xref ref-type="bibr" rid="CR25">25</xref>]. Another transcriptomic study on several stage 1 and stage 3 aGCT samples identified 24 genes whose expression significantly fluctuated between stages [<xref ref-type="bibr" rid="CR26">26</xref>]. More recently, whole genome sequencing of a large aGCTs cohort indicated <italic>TP53</italic> and <italic>DICER1</italic> as potential drivers in these tumors and found a higher mutational burden in recurrent tumors, as compared to primary AGCTs [<xref ref-type="bibr" rid="CR27">27</xref>]. However, these molecular events are not frequent as FOXL2<sup>C134W</sup>. Recent publications investigated the FOXL2<sup>C134W</sup> pathogenicity from a transcriptional perspective. Notably, Carles et al. developed an inducible FOXL2<sup>C134W</sup> stable luteinized cell line (SVOG3e) [<xref ref-type="bibr" rid="CR28">28</xref>] which demonstrated that FOXL2<sup>C134W</sup> mutation may precisely alter DNA binding specificity. The study revealed low numbers of target genes and the authors noted the SVOG3e cell line may not respond appropriately to FOXL2<sup>C134W</sup>. This may be possibly due to the absence of the needed partner SMAD3. Indeed, it is well known that SMAD3, a central element of the TGF&#x003b2; pathway, is essential for the FOXL2<sup>C134W</sup> activity [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>]. In line with this, a recent study by Weis-Banke et al. [<xref ref-type="bibr" rid="CR37">37</xref>], showed that FOXL2<sup>C134W</sup> and the TGF&#x003b2; pathway are together two important potential therapeutic targets. Indeed, using FOXL2<sup>C134W</sup> overexpression and silencing molecular approaches in a non-luteinized GC cell line (HGrC1) treated with TGF&#x003b2;, they showed that SMAD4 is also an important FOXL2<sup>C134W</sup> partner and the TGF&#x003b2;/FOXL2<sup>C134W</sup> molecular events trigger the expression of oncogenic, EMT, and stemness pathways in an aGCT model [<xref ref-type="bibr" rid="CR37">37</xref>]. It is well accepted that TGF&#x003b2; has an important role in tumor progression and involves SMAD mediators that control expression of hundreds of genes in different ways in diverse contexts and physiologies [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>] although additional investigations are needed to find its specific action(s) in aGCTs.</p><p id="Par19">To further demonstrate the role of SMAD3 as a molecular partner of FOXL2<sup>C134W</sup> in aGCT progression on a genome-wide level, we carried out RNA-seq analysis in HGrC1 overexpressing FOXL2<sup>C134W</sup> together with SMAD3, compared to FOXL2<sup>WT</sup>/SMAD3 as a control. We further explored the FOXL2 antagonistic tumor-suppressive transcription factor FOXO1 [<xref ref-type="bibr" rid="CR35">35</xref>] to study its influence on the SMAD3/FOXL2<sup>C134W</sup> induced alterations. FOXO factors are considered as tumor suppressors for their parts in the initiation of apoptotic process and in the cell cycle arrest [<xref ref-type="bibr" rid="CR40">40</xref>]. We report that FOXL2<sup>C134W</sup> over-expression was associated with altered signaling pathways previously recognized by transcriptomic studies from GC in situ [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR37">37</xref>], and additionally identified novel candidate FOXL2<sup>C134W</sup> targets. Furthermore, we observed that FOXO1 strongly mitigated the overall FOXL2<sup>C134W</sup> action with important implications for both aGCT onset and future therapeutic development.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Plasmids and reagents</title><p id="Par20">Expression plasmid encoding N-terminally Flag-tagged hFOXO1-3A (#13,508) was purchased from Addgene (Cambridge, MA, pCDNA3 backbone). FOXO1-3A has Ala residue substitutions at Thr-24, Ser-256 and Ser-319 and is thus constitutively active. The usage of this mutant was based on the fact that protein remains in the nucleus due to the inability of insulin/growth factor signaling to phosphorylate the mutated residues. Like FOXL2 wild type (FOXL2<sup>WT</sup>), the FOXL2<sup>C134W</sup> mutant is also localized in the nucleus [<xref ref-type="bibr" rid="CR9">9</xref>] and thus FOXO1-3A is the best construct for our transcriptomic study. N-terminally Flag-tagged human FOXL2wt (pCS2&#x02009;+&#x02009;backbone) was kindly given by Dr. Louise Bilezikjian [<xref ref-type="bibr" rid="CR33">33</xref>] and its mutant (FOXL2<sup>C134W</sup>) was made in our laboratory as previously reported [<xref ref-type="bibr" rid="CR41">41</xref>]. The expression plasmids encoding human SMAD3 were kindly provided by Drs. Kohei Miyazono [<xref ref-type="bibr" rid="CR42">42</xref>] and Louise Bilezikjian [<xref ref-type="bibr" rid="CR33">33</xref>].</p></sec><sec id="Sec4"><title>HGrC1 cell culture</title><p id="Par21">HGrC1 cells were kindly provided by Drs. T. Nakamura and A. Iwase, and their properties and derivation described earlier [<xref ref-type="bibr" rid="CR43">43</xref>]. Notably, these cells bear two normal alleles of the FOXL2 gene [<xref ref-type="bibr" rid="CR34">34</xref>]. Cells were cultured in a standard incubator at 37&#x000a0;&#x000b0;C in DMEM-F12 medium (catalog #12,400&#x02013;024, Thermo Fisher Scientific, Waltham, MA) complemented with antibiotics (penicillin and streptomycin) and 10% FBS (#F6178, Sigma-Aldrich). HGrC1 cells at passage 14 were used for all the experiments in this study. HGrC1 cells seeded into 6-well tissue culture plates (1&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells/well). Medium was replaced after 24&#x000a0;h with serum-free DMEM-F12 (complemented with antibiotics), and transfection was performed using the above described plasmids for 4&#x000a0;h with Lipofectamine 3000 reagents (catalog #L3000008, Thermo Fisher Scientific) following manufacturer&#x02019;s procedures. After 4&#x000a0;h, the medium was replaced with new serum free DMEM-F12 and transfected cells were cultured at 37&#x000a0;&#x000b0;C for 24&#x000a0;h.</p></sec><sec id="Sec5"><title>RNA-seq data generation</title><p id="Par22">After 4&#x000a0;h transfection and additional culture for 24&#x000a0;h in serum free DMEM-F12, HGrC1 cells (15 samples including 3 replicates for 5 conditions) were lysed using TRIzol reagent (catalog #15596026, Thermo Fisher Scientific) and RNA was extracted with Direct-zol RNA MiniPrep kit (#R2052, Zymo Research, Irvine, CA). RNA Quality control was performed by Agilent TapeStation (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1). RNA-seq libraries were prepared using the TrueSeq Stranded mRNA Library Prep (Illumina, catalog #20020595) and sequenced using an illumina HiSeq4000 Platform using 75-bp single-end reads, to an average of 22.9&#x02009;&#x000b1;&#x02009;3.4 million reads per sample.</p></sec><sec id="Sec6"><title>Western Blot</title><p id="Par23">For protein quantification, additional five samples that were cultured in parallel were lysed in lysis buffer (RIPA buffer, catalog #89901, Thermo Fisher Scientific), phosphatase inhibitor cocktail (#78420, Thermo Fisher Scientific) and protease inhibitor cocktail (#P8340, Sigma-Aldrich), and Pierce BCA protein assay kit was used for total protein quantification (#23227, Thermo Fisher Scientific). NuPAGE LDS sample buffer 4X (#NP0007, Thermo Fisher Scientific) and &#x003b2;-mercaptoethanol (#6010, Calbiochem, Billerica, MA) were added to cell lysates, and samples were denaturized at 95&#x000a0;&#x000b0;C for 5&#x000a0;min. Proteins separation occurred on 8&#x02013;12% SDS-PAGE gels and with subsequent transfer to nitrocellulose membranes. Membranes were then incubated for 1&#x000a0;h with blocking solution (BSA, #A30075-100, Research Products International, Mount Prospect, IL), and with primary antibodies overnight at 4&#x000a0;&#x000b0;C. Membranes were washed three times, then incubated for 1&#x000a0;h with secondary antibodies conjugated to infrared fluorescent dyes excitable at 800&#x000a0;nm (IRDye 800CW, Li-COR-USA) to visualize the desired antigens using an 800&#x000a0;nm laser scanner (Odyssey, Licor, USA). Quantification of protein levels was performed by IR fluorescence detection (Odyssey, Licor, USA) and analysis was performed with ImageJ.</p></sec><sec id="Sec7"><title>RNA-seq bioinformatics analyses</title><p id="Par24">Differential expression analysis was performed with RNA-seq [<xref ref-type="bibr" rid="CR44">44</xref>]. To quantify transcript abundance for each sample we used salmon (1.1.0) [<xref ref-type="bibr" rid="CR45">45</xref>] with default parameters and using hg38 set as the reference genome for reads mapping. The data was subsequently imported in R using the tximport package [<xref ref-type="bibr" rid="CR46">46</xref>] and processed with the DESeq2 package [<xref ref-type="bibr" rid="CR47">47</xref>]. A total of 37,787 genes were analyzed. For Principal Component Analysis we normalized the raw transcript counts using <italic>variance stabilized transformation</italic> (<italic>vst</italic> function from DESeq2) and applied the <italic>plotPCA</italic> function from DESeq2, using the default 500 most variable genes to compute the principal components as well as using all expressed genes. Loadings for each gene and each PC were extracted from the &#x0201c;rotation&#x0201d; field using the <italic>pca</italic> function in R from the top 500 most variable genes and divided by the sum of loadings for all genes in each PC. All heatmaps were generated using vst expression values and the heatmap package in R, excluding genes from over-expressed vectors. Differential expression analysis was performed using DESeq2 comparing different pairs of conditions, and a threshold of Benjamini&#x02013;Hochberg corrected p-value of 0.05 was chosen to define differentially expressed genes for each comparison.</p></sec><sec id="Sec8"><title>Analysis of publicly available FOXL2 ChIP-Seq data</title><p id="Par25">To estimate the fraction of genes with FOXL2 binding sites we used two publicly available human FOXL2 ChIP-seq dataset: one from TGF&#x003b2;-treated HGrC1 cells ectopically expressing FOXL2 or FOXL2<sup>C134W</sup> [<xref ref-type="bibr" rid="CR37">37</xref>] and the other from an immortalized granulosa cell line (SVOG3e) with inducible expression of V5-tagged FOXL2<sup>C134W</sup> protein [<xref ref-type="bibr" rid="CR28">28</xref>]. For the first one (ChIP1), BAM files from FOXL2<sup>C134W</sup> and the negative empty vector control were obtained from the authors and peaks were called using MACS2 [<xref ref-type="bibr" rid="CR48">48</xref>] callpeak with default setting and using q-value cutoff of peak detection of 0.01 (&#x02013; q 0.01). For the second (ChIP2), we obtained the peak coordinates from GEO (GSE126171) from 4 replicates at 12hrs induction of V5-tagged FOXL2<sup>C134W</sup> and merged peaks coordinates of the replicates. Peaks BED files from the above ChIP-Seq were intersected with a&#x02009;&#x000b1;&#x02009;5&#x000a0;kb window from the transcription start site (TSS) of human genes (genecode v35 and genecode v19 respectively for ChIP1 and ChIP2) to identify genes with FOXL2<sup>C134W</sup> binding around their promoter region (<italic>n</italic>&#x02009;=&#x02009;9,939 and <italic>n</italic>&#x02009;=&#x02009;11,697, respectively). Enrichment for genes with FOXL2 binding was calculated using Fisher&#x02019;s exact test in R, comparing DEGs versus non-DEGs.</p><p id="Par26">To better characterize differential gene expression between FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup> conditions, we performed enrichment analysis for differences in binding between FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup>. To identify differential binding sites, we downloaded triplicate ChIP-Seq data from TGF&#x003b2;-treated HGrC1 cells ectopically expressing FOXL2<sup>WT</sup>, FOXL2<sup>C134W</sup> or empty vectors from GEO (GSE138496) [<xref ref-type="bibr" rid="CR37">37</xref>]. Sequencing reads were filtered and trimmed for quality using Trim Galore! (<ext-link ext-link-type="uri" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/trim_galore">http://www.bioinformatics.babraham.ac.uk/projects/trim_galore</ext-link>) and subsequently aligned to the hg38 reference genome using bowtie2 [<xref ref-type="bibr" rid="CR49">49</xref>]. Duplicate reads were removed from the alignment using picard MarkDuplicates (<ext-link ext-link-type="uri" xlink:href="http://broadinstitute.github.io/picard/">http://broadinstitute.github.io/picard/</ext-link>). A consensus set of peaks was generated using MACS2 with parameters as above, from combined FOXL2 and FOXL2<sup>C134W</sup> BAM files and using the empty vector BAMs as background. A total of 46,235 peaks were identified and, for each peak, the number of mapped reads in each triplicate of FOXL2<sup>WT</sup>and FOXL2<sup>C134W</sup> was quantified using featureCounts [<xref ref-type="bibr" rid="CR50">50</xref>]. The obtained matrix of peak x sample was used to determine differential peaks between FOXL2<sup>WT</sup>and FOXL2<sup>C134W</sup> using DESeq2. Peaks were intersected with a&#x02009;&#x000b1;&#x02009;10&#x000a0;kb window from TSSs of human genes (genecode v35). Enrichment for genes with differential FOXL2 binding was calculated using Fisher&#x02019;s exact test in R.</p></sec><sec id="Sec9"><title>Gene ontology enrichment analyses</title><p id="Par27">For Gene Ontology Enrichment (GO) analyses, we used Metascape [<xref ref-type="bibr" rid="CR51">51</xref>] with default parameters. To reduce the confounding effect on gene expression derived from variable overexpression of the proteins from the plasmids across samples, we removed the terms that were associated with the expression of FOXL2 and/or SMAD3. In order to do so, we performed Gene Set Enrichment Analysis (GSEA) and identified gene ontology terms significantly associated with FOXL2 and/or SMAD3. In detail, the GSEA tool (<ext-link ext-link-type="uri" xlink:href="http://www.broad.mit.edu/gsea">http://www.broad.mit.edu/gsea</ext-link>) for continuous phenotypes was used to identify gene annotation categories correlated with the genes of interest<italic>.</italic> For each gene of interest (FOXL2 or SMAD3), GSEA was run with the expression of that gene across samples set as the &#x0201c;continuous phenotype&#x0201d;; significant gene annotation sets with activity coordinated to the select gene were identified with adjusted <italic>p</italic>-value&#x02009;&#x0003c;&#x02009;0.25. The list of significant gene annotation sets is provided in Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S1. These annotation terms were removed from the results obtained with Metascape, <italic>i.e.</italic> from each list of terms enriched for differentially expressed genes throughout this investigation.</p></sec><sec id="Sec10"><title>Real-time PCR validation</title><p id="Par28">An independent transfection experiment was carried out for qPCR validation as described above. RNA was extracted with Direct-zol RNA MiniPrep kit (#R2052, Zymo Research, Irvine, CA) following manufacturer&#x02019;s protocol. High-Capacity cDNA Reverse Transcription Kit (#4368814, Thermo Fisher Scientific) was used to reverse transcribe 1&#x000a0;&#x003bc;g RNA. mRNA expression was quantified by q-RT-PCR amplification of cDNA using SYBR Green PCR Master Mix (#4309155, Thermo Fisher Scientific) and a Bio-Rad CFX384 Real-Time PCR Detection System. Q-RT-PCR was performed with primer assays from Sigma (#KSPQ12012G) and Qiagen (#330001) targeting the genes <italic>TGFB1</italic>, <italic>TGFB2</italic>, <italic>ZYX</italic>, <italic>NFKBIA</italic>, <italic>SDC4</italic>, <italic>COL4A2</italic>, <italic>BAZ2A</italic>, <italic>SMARCA4</italic>, and <italic>HSPG2</italic>. Primer assay efficiencies were guaranteed by the manufacturer. Target gene expression was normalized on GAPDH and ACTIN expression.</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Transcriptomics analysis of the human granulosa HGrC1 cell in presence of FOXL2<sup>C134W</sup></title><p id="Par29">To investigate the transcriptional changes associated with the SMAD3/FOXL2<sup>C134W</sup> program, and its interaction with FOXO1, HGrC1 cells transiently expressing SMAD3 and FOXL2<sup>WT</sup>/FOXL2<sup>C134W</sup>, with or without FOXO1-3A (FOXO1 hereafter), were profiled using RNA sequencing (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig. S1 shows the efficiency of transfection and demonstrates balanced protein expression of FOXL2<sup>WT</sup>, FOXL2<sup>C134W</sup> and FOXO1. Principal Component Analysis (PCA) was calculated on variance stabilized transformation (<italic>vst</italic>)-normalized expression values from the top 500 most variable genes across samples (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b), as well as using all expressed 37,787 genes (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S3). The variation between samples was largely explained by the de novo gene expression from overexpressing plasmids (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig. S3), with samples of the same conditions clustering closer together, indicating good reproducibility between replicates. In particular, <italic>FOXO1</italic>, <italic>FOXL2</italic>, and <italic>SMAD3</italic> were the top 3 genes contribution to the first 3 PCs (38% variance explained, Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S4). To identify genes selectively induced by FOXL2 or FOXL2<sup>C134W</sup>, we next assessed differential expression analysis between FOXL2<sup>WT</sup> and controls, FOXL2<sup>C134W</sup> and controls, and FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup>, and identified a total of 452, 939 and 717 differential expressed genes (DEGs, q&#x02009;&#x0003c;&#x02009;0.05, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S1) genes respectively, many of which were shared among the different conditions (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c). Of note, FOXL2<sup>C134W</sup> induced more changes with respect to the overexpression of the wild type protein, possibly indicating an enhanced binding and/or transcriptional capacity.<fig id="Fig1"><label>Fig. 1</label><caption><p>Transcriptome analysis of the human granulosa HGrC1 cell line under different transfection conditions. <bold>a</bold> Schematic summary of study design. FOXL2<sup>WT</sup>/FOXL2<sup>C134W</sup> were in pCS2&#x02009;+&#x02009;expression plasmid constructs; FOXO1<sup>3A</sup> in pCDNA3 expression construct to minimize promoter competition. <bold>b</bold> Principal component 1 and 2 from all samples of the study, color-coded as indicated in the legend. Principal components were calculated on vst-normalized expression values from the top 500 most variable genes across samples. (SMAD3 was co-transfected with the other protein constructs per Methods but is omitted in the legend for brevity). <bold>c</bold> Venn diagram showing the number of differential genes (DESeq, q&#x02009;&#x0003c;&#x02009;0.05) identified in 3 pairs of conditions: FOXL2<sup>WT</sup> vs Vectors, FOXL2<sup>C134W</sup> vs Vectors and FOXL2<sup>C134W</sup> vs FOXL2<sup>WT</sup>. <bold>d</bold> Heatmap and hierarchical clustering of the 717 DEGs between FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup> in all 5 conditions. Expression values are z-score normalized across samples (columns)</p></caption><graphic xlink:href="12967_2021_2754_Fig1_HTML" id="MO1"/></fig></p><p id="Par30">When performing hierarchical clustering of the 717 DEGs between FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup> in all 5 conditions (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>d), we observed different patterns of expression with respect to the control, with the most common pattern being genes upregulated in FOXL2<sup>C134W</sup> with respect to FOXL2<sup>WT</sup> and to the control, but not upregulated in FOXL2<sup>WT</sup> respect to the controls. This suggests that a majority of the expression changes involved genes that were not canonical targets of FOXL2 wild type, but became target of gain-of-function FOXL2<sup>C134W</sup>, in line with a previous study by Weis-Banke et al. [<xref ref-type="bibr" rid="CR37">37</xref>]. On the other hand, samples that overexpressed FOXO1 in addition to FOXL2<sup>C134W</sup> or FOXL2<sup>WT</sup> clustered closer to the controls than their counterpart without FOXO1, suggesting that FOXO1 attenuated the effects of overexpressing FOXL2<sup>C134W</sup> or FOXL2<sup>WT</sup>. These two observations will be further investigated in the following analyses.</p></sec><sec id="Sec13"><title>Gene ontology analysis of DEGs of FOXL2<sup>C134W</sup> vs FOXL2<sup>WT</sup></title><p id="Par31">To evaluate the functional significance of the genome-wide alterations in gene expression triggered by FOXL2<sup>C134W</sup>, we performed Gene Ontology (GO) analysis on DEGs, specifically focusing on the differences between FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup>. The volcano plot (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a) and heatmap analysis (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig. S5) revealed significantly upregulated (<italic>e.g.</italic> SMARCA4, RRBP1, FLNA) and downregulated genes (e.g. NFKBIA, TAP1, CXCL8). Among the upregulated and downregulated differentially expressed genes (DEGs), many are associated with the (ECM) extracellular matrix (HSPG2, COL4A2, COL5A1) or cellular interaction with it (FLNA, FLNC), chromatin remodeling (SMARCA4, EP400, BAZ2A), and PI3K/AKT and inflammation pathways (AMIGO2, XBP1).<fig id="Fig2"><label>Fig. 2</label><caption><p>Gene Ontology enrichment analysis of differentially expressed genes (DEGs) between FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup>. <bold>a</bold> Volcano plot showing in pink DEGs between FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup> (DESeq, q&#x02009;&#x0003c;&#x02009;0.05). The genes FOXL2 and SMAD3 were omitted from the plot. <bold>b</bold>, <bold>c</bold> Gene ontology enrichment analysis using up-regulated genes in FOXL2<sup>C134W</sup> transfected cells (<bold>b</bold>, n&#x02009;=&#x02009;487), and down-regulated genes in FOXL2<sup>C134W</sup> transfected cells (C, n&#x02009;=&#x02009;230). The red line indicates p-value cutoff for p&#x02009;&#x0003c;&#x02009;0.05. Gene ontology enrichment p-values were calculated using Metascape [<xref ref-type="bibr" rid="CR51">51</xref>]. GO terms associated with expression of FOXL2 and/or SMAD3 were removed from the results (see Methods and Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Tables S2&#x02013;4)</p></caption><graphic xlink:href="12967_2021_2754_Fig2_HTML" id="MO2"/></fig></p><p id="Par32">Enrichment analysis [<xref ref-type="bibr" rid="CR51">51</xref>] of pathways was performed on 487 upregulated (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b) and 230 downregulated genes (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c). The upregulated genes were highly enriched for gene annotation categories from oncogenic pathways, including Signaling by Receptor Tyrosine Kinases, and Proteoglycans in Cancer, Tissue Morphogenesis and response to growth factor. Interestingly, GO categories enriched for downregulated genes (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c) included pathways often suppressed by oncogenes. These contained Wound Healing and the PID P53 Downstream pathways. Overall these data support the pathognomic role of FOXL2<sup>C134W</sup>/SMAD3 complex as a driver of specific and selective oncogenic molecular events (Genes and GO categories in Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S2&#x02013;4).</p></sec><sec id="Sec14"><title>Identification of direct FOXL2 targets among DEGs between FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup></title><p id="Par33">To determine whether DEGs were direct targets of FOXL2<sup>C134W</sup>, we next annotated gene promoters using available FOXL2<sup>C134W</sup> ChIP-seq from the recent studies by Weis-Banke et al. [<xref ref-type="bibr" rid="CR37">37</xref>] (ChIP1) in TGF&#x003b2;-treated HGrC1, and by Carles et al<italic>.</italic> [<xref ref-type="bibr" rid="CR28">28</xref>], which included inducible expression of FOXL2<sup>C134W</sup> in human SVOG3e cell line (ChIP2). A large fraction (44&#x02013;40%) of DEGs between FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup> had a FOXL2<sup>C134W</sup> binding site near their promoters (313 out of 717 using the HGrC1 ChIP-seq and 291 using the SVOG3e ChIP-Seq), which was a significantly higher proportion than in non-DEGs (Fisher&#x02019;s exact test, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a overall p&#x02009;=&#x02009;9.8&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;51</sup>; upregulated p&#x02009;=&#x02009;3.7&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;37</sup>; and downregulated p&#x02009;=&#x02009;5.2&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;15</sup>; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>b overall p&#x02009;=&#x02009;9.9&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;39</sup>; upregulated p&#x02009;=&#x02009;6.4&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;26</sup>; and downregulated p&#x02009;=&#x02009;3.8&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;14</sup>). The presence of these binding sites suggests that the changes in gene expression in our system are due in large extent to differences in FOXL2 binding.<fig id="Fig3"><label>Fig. 3</label><caption><p>Identification of direct FOXL2 targets among DEGs between FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup>. <bold>a</bold> Enrichment of FOXL2 binding in DEGs between FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup> with respect to non-DEGs using FOXL2<sup>C134W</sup> ChIP-seq binding site in TGF&#x003b2;-treated HGrC1 (ChIP1) [<xref ref-type="bibr" rid="CR37">37</xref>] and another <bold>b</bold> using FOXL2<sup>C134W</sup> ChIP-seq binding site in SVOG3e cell line (ChIP 2) [<xref ref-type="bibr" rid="CR28">28</xref>]. p-values and odds ratios (OR) are from two-tailed Fisher&#x02019;s exact test. <bold>c</bold> Heatmap of the 717 DEGs between FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup> grouped into 6 categories based on direction of expression in FOXL2<sup>C134W</sup>, FOXL2<sup>WT</sup> and empty vector, as depicted in the diagrams. For each category, the top 30 DEGs (or less for smaller groups) are listed. <bold>d</bold> Enrichment of differential FOXL2<sup>C134W</sup> vs FOXL2<sup>WT</sup> binding (see Methods) at promoters of genes in each of the 6 DEG categories, color-coded as in (<bold>c</bold>). p-values and odds ratios (OR) are from two-tailed Fisher&#x02019;s exact test. <bold>e</bold> Genome-browser screenshots of FOXL2<sup>WT</sup> and FOXL2<sup>C134W</sup> ChIP-Seq in TGF&#x003b2;-treated HGrC1 [<xref ref-type="bibr" rid="CR37">37</xref>], showing differential binding at the TGFB2 (top), SMARCA4 (middle) and NFKBIA (bottom) promoter regions. <bold>f</bold> Venn diagram (upper panel) showing the number of differential genes (q&#x02009;&#x0003c;&#x02009;0.1) identified in FOXL2<sup>C134W</sup> vs FOXL2<sup>WT</sup> (20 DEGs) from the present study and from adult granulosa cell tumor patient samples vs control samples (111 DEGs) previously published [<xref ref-type="bibr" rid="CR25">25</xref>]. The lower panel shows heatmap of the common identified 11 genes. For each gene, expression values were z-score normalized across samples. Genes are annotated for presence or absence of a FOXL2<sup>C134W</sup> ChIP-seq binding site in TGF&#x003b2;-treated HGrC1 (ChIP1) [<xref ref-type="bibr" rid="CR37">37</xref>] and a FOXL2<sup>C134W</sup> ChIP-seq binding site in a SVOG3e cell line (ChIP 2) [<xref ref-type="bibr" rid="CR28">28</xref>]</p></caption><graphic xlink:href="12967_2021_2754_Fig3_HTML" id="MO3"/></fig></p><p id="Par34">To better characterize those targets differentially modified by FOXL2<sup>C134W</sup>, we grouped the 717 DEGs in six subsets (labeled as Cat_1 to Cat_6) of upregulated and downregulated genes according to different patterns of expression in FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup> conditions with respect to the vector, as depicted in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>c. For example, category 1 (Cat_1) included genes, such as <italic>ACTN1</italic> and <italic>TGFB2,</italic> that were upregulated in both mutant and wild-type conditions, while category 2 (Cat_2) included genes, such as <italic>SMARCA4, HSPG2</italic> and <italic>BAZ2A</italic>, that were upregulated only in FOXL2<sup>C134W</sup>.</p><p id="Par35">To understand if these effects could be explained by differences in FOXL2 binding, rather over-expression artifacts, we analyzed the enrichment for differential ChIP-Seq peaks in each category (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>d). Differential peaks were calculated using DESeq2 between FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup> ChIP-Seq in TGF&#x003b2;-treated HGrC1 from by Weis-Banke et al. [<xref ref-type="bibr" rid="CR37">37</xref>]. Out of a total of 46,235 sites, we identified 12,515 differential peaks (q&#x02009;&#x0003c;&#x02009;0.05), where 10,353 had stronger FOXL2<sup>C134W</sup> signal (i.e. FOXL2<sup>C134W</sup> showed a stronger binding in an existing FOXL2 site or bound to a completely new site), and only 2,162 had stronger FOXL2<sup>WT</sup> signal. Examples of differential peaks at the <italic>TGFB2</italic>, <italic>SMARCA4</italic> and <italic>NFKBIA</italic> promoters are shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>e.</p><p id="Par36">When comparing the fraction of genes with differential peaks in each category, we found that in the upregulated DEGs, Cat_2 and Cat_3, which had discordant effect with respect to the vector, had the highest enrichment (Fisher&#x02019;s exact test, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>d, odds ratios&#x02009;=&#x02009;3.1 and 6.5, and p&#x02009;=&#x02009;8&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;25</sup> and 7.3&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;6</sup> respectively), while Cat_1, which had concordant effect with respect to the vector, was not significantly enriched for differential peaks (OR&#x02009;=&#x02009;1.7, p&#x02009;=&#x02009;0.091). These data suggest that the more dramatic changes in expression were more likely to be due to alteration of FOXL2 binding due to the gain-of-function mutation. For the down-regulated DEGs categories (Cat 4 to 6) we did not observe the same enrichment patterns, perhaps due to the smaller number of genes, or more complex mechanisms leading to gene repression.</p><p id="Par37">Additionally, we performed GO enrichment analysis of the four largest categories of DEGs (Cat_1, Cat_2, Cat_4 and Cat_5, Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig.&#x000a0;S6) and found different enrichment for oncogenic regulating pathways such as <italic>Cytoskeleto</italic>n (Cat_1), <italic>grow factor signaling</italic> (Cat_2), <italic>NF-kappaB and Tyrosine Kinase Signaling</italic> (Cat_4), <italic>Lysosome</italic> (Cat_5). Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig.&#x000a0;S7 includes validation by qPCR for mRNA levels of several genes of these categories (TGFB1, TGFB2, ZYX, NFKBIA and SDC4) in an independent experiment showing that these gene followed the same pattern of our analysis.</p><p id="Par38">To compare our findings with those from overexpression of FOXL2<sup>C134W</sup> in the human SVOG3e cell line [<xref ref-type="bibr" rid="CR28">28</xref>], we intersected our list of 939 DEGs of FOXL2<sup>C134W</sup> vs. Vector with the corresponding published list of 471 DEGs, and identified 90 common genes (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig.&#x000a0;S8). Among these genes, we found TGFB2, EGR1, NFKBIZ, SDC, and SDCBD which are homologues genes to the obtained ones in our previous analysis (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>c, d). Chip-seq data were also compared to the DEGs (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig.&#x000a0;S7B). Gene Ontology analysis of these 90 genes revealed cancer-related regulatory pathways (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig.&#x000a0;S8C).</p><p id="Par39">To complete our comparative analysis with the most recent transcriptomic data, we also intersected our FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup> DEGs list (717 genes) to the those DEGs in Weis-Banke et al. (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig.&#x000a0;S9). In addition, 29 common genes identified via Chip-seq data [<xref ref-type="bibr" rid="CR37">37</xref>] were also compared to the DEGs (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig.&#x000a0;S9A, B). Analysis of these genes showed an involvement reproduction and tumorigenesis-related GO pathways like cell-adhesion regulation and negative regulation of wound healing (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig.&#x000a0;S9C). Finally, comparing our FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup> DEGs (717 genes) to transcriptomic data from aGTC patients published by Benayon et al. [<xref ref-type="bibr" rid="CR25">25</xref>], we were able to categorize 11 genes (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>e), of which at least 3 (TGFB2, POLQ, GLI2) are <italic>bona fide</italic> FOXL2 targets [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR37">37</xref>] (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>e). TGFB2 is the most consistent FOXL2<sup>C134W</sup>-modulated candidate and was present as target and upregulated genes in every analysis performed. These global results of our transcriptomic support the putative key role of FOXL2<sup>C134W</sup> in aGCT tumorigenesis playing as regulator of oncogene (TGFB2, GLI2, EGR1) and as modulator of ECM genes (HSPG2, SDC4, COL5A1) and chromatin/nucleic acid remodeling (SMARCA4, BAZ2A).</p></sec><sec id="Sec15"><title>FOXO1 overexpression mitigates FOXL2<sup>C134W</sup> gene expression profile.</title><p id="Par40">We next assessed the effect of FOXO1 overexpression in addition to FOXL2<sup>C134W</sup> on gene expression profiles. Interestingly, the number of DEGs between FOXL2<sup>C134W</sup> in the presence of FOXO1, and FOXL2<sup>WT</sup> were much lower (230) relative to the number of DEGs between FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup> (717, of which 130 in common), suggesting that the transcriptional changes of FOXL2<sup>C134W</sup> compared to FOXL2<sup>WT</sup> are largely mitigated by the co-expression of FOXO1 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a). This notion is supported by comparing the overall effect size for DEG between FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup> (n&#x02009;=&#x02009;717), with or without FOXO1 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b). While the log2FC are generally consistent across the two comparisons (FOXL2<sup>C134W</sup>&#x02009;+&#x02009;FOXO1 vs FOXL2<sup>WT</sup> and FOXL2<sup>C134W</sup> vs FOXL2<sup>WT</sup>), the linear regression slope &#x000df; was 0.58 (less than 1), suggesting that up- or down-regulation of genes relative to the FOXL2<sup>WT</sup> is attenuated by approximately 40% in presence of FOXO1, in our model system. A different estimation of this effect was measured by the absolute fold change of FOXL2<sup>C134W</sup>&#x02009;+&#x02009;FOXO1 vs FOXL2<sup>C134W</sup> at the 230 genes and resulted in an average of 15% modulation (&#x000b1;&#x02009;19%, standard deviation). To further identify potential targets of FOXL2<sup>C134W</sup> that are significantly modulated by FOXO1, we identified DEGs between FOXL2<sup>C134W</sup>&#x02009;+&#x02009;FOXO1 and FOXL2<sup>C134W</sup> and obtained 58 genes, having an average absolute fold change of 44%. Thirty-nine of these genes were in common with those between FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup> (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c). These 39 genes (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>d), were downregulated in the FOXL2<sup>C134W</sup>&#x02009;+&#x02009;FOXO1 vs FOXL2<sup>C134W</sup> comparison, and vice versa. These genes were also compared against FOXL2 ChIP-seq from the recent studies by Weis-Banke et al. [<xref ref-type="bibr" rid="CR37">37</xref>] and by Carles et al<italic>.</italic> [<xref ref-type="bibr" rid="CR28">28</xref>]. Among these, 10 members were <italic>bona fide</italic> targets (including HSPG2, COL4A2 and BAZ2A). In particular, we identified the GO peptidyl-lysine modification pathway, implying that FOXO1 acts upon the chromatin remodeling triggered by FOXL2<sup>C134W</sup>. Moreover, other genes recognized in the ECM regulation were detected (HSPG2, COL4A2, COL5A1, COL18A1, DLG5). Independent qPCR validation of the BAZ2A, SMARCA4, COL4A2, and HSPG2 mRNA levels, modulated in presence of FOXO1, is depicted in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>f. These data build on our prior identification of FOXO1 as a modulator of FOXL2 and provide the first molecular basis for FOXO1 in aGCT reprogramming.<fig id="Fig4"><label>Fig. 4</label><caption><p>Effect of FOXO1 overexpression on FOXL2<sup>C134W</sup> &#x02013; modified genes. <bold>a</bold> Venn diagram showing the number of differential genes (DESeq, q&#x02009;&#x0003c;&#x02009;0.05) identified in FOXL2<sup>C134W</sup> vs FOXL2<sup>WT</sup> and FOXL2<sup>C134W</sup>&#x02009;+&#x02009;FOXO1 vs FOXL2<sup>WT</sup>. <bold>b</bold> Scatter plot of the effect sizes (log2-fold change) of DEGs between FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup>, with (y-axis) and without (x-axis) the addition of FOXO1. Genes that were differentially expressed also when adding FOXO1<sup>3A</sup> are shown in black (n&#x02009;=&#x02009;130), while genes that were differentially expressed only without FOXO1<sup>3A</sup> addition are shown in purple (n&#x02009;=&#x02009;587). The slope (&#x000df;) of the linear relationship between the two effect sizes is shown on top of the plot. <bold>c</bold> Venn diagram showing the number of differential genes (DESeq, q&#x02009;&#x0003c;&#x02009;0.05) identified in FOXL2<sup>C134W</sup> vs FOXL2<sup>WT</sup> and FOXL2<sup>C134W</sup>&#x02009;+&#x02009;FOXO1 vs FOXL2<sup>C134W</sup>. <bold>d</bold> Heatmap with gene clustering of the 39 DEGs in both FOXL2<sup>C134W</sup> vs FOXL2<sup>WT</sup> and FOXL2<sup>C134W</sup>&#x02009;+&#x02009;FOXO1 vs FOXL2<sup>C134W</sup> comparisons. For each gene, expression values were z-score normalized across samples. Genes are annotated for presence or absence of a FOXL2<sup>C134W</sup> ChIP-seq binding site in TGF&#x003b2;-treated HGrC1 (ChIP1) [<xref ref-type="bibr" rid="CR37">37</xref>] and a FOXL2<sup>C134W</sup> ChIP-seq binding site in a SVOG3e cell line (ChIP 2) [<xref ref-type="bibr" rid="CR28">28</xref>]. <bold>e</bold> Metascape GO analysis of the 39 DEGs in both FOXL2<sup>C134W</sup> vs FOXL2<sup>WT</sup> and FOXL2<sup>C134W</sup>&#x02009;+&#x02009;FOXO1 vs FOXL2<sup>C134W</sup> comparisons. The red line indicates p-value cutoff for p&#x02009;&#x0003c;&#x02009;0.05. GO terms associated with expression of FOXL2 and/or SMAD3 were removed from the results (see Methods). <bold>f</bold> qPCR validation of the RNAseq expression data in FOXO1 modulated genes (BAZ2A, SMARCA4, COL4A2, and HSPG2). Graphs show fold change means&#x02009;&#x000b1;&#x02009;s.e.m relative expression to FOXL<sup>WT</sup> following normalization to the housekeeping gene. Data were analyzed using the two-tailed unpaired t-test (*p&#x02009;&#x0003c;&#x02009;0.05, **p&#x02009;&#x0003c;&#x02009;0.01, ***p&#x02009;&#x0003c;&#x02009;0.001)</p></caption><graphic xlink:href="12967_2021_2754_Fig4_HTML" id="MO4"/></fig></p></sec></sec><sec id="Sec16"><title>Discussion</title><p id="Par41">In contrast to the rarer juvenile Granulosa Cell tumors, the bulk of granulosa cell tumors are the adult type (aGCT), which occur peri to post-menopausally [<xref ref-type="bibr" rid="CR52">52</xref>&#x02013;<xref ref-type="bibr" rid="CR54">54</xref>]. Patients characteristically present elevated estrogen levels and postmenopausal bleeding [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. Almost all aGCTs bear the unique somatic mutation FOXL2<sup>C134W</sup> [<xref ref-type="bibr" rid="CR56">56</xref>], which appears essential to the aGCT development [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR57">57</xref>&#x02013;<xref ref-type="bibr" rid="CR60">60</xref>]. However, its pathogenic role in the aGCTs has been investigated only recently and the FOXL2<sup>C134W</sup> transcriptional action in aGCTs is still currently studied. These investigations are not trivial, as transcriptomic studies on rare tumors&#x02014;like aGCTs&#x02014;face difficulties in the procurement good quality RNA samples. Control samples from healthy human granulosa cells without any previous treatment (HGC or hormones) are similarly limited. Accordingly, only few transcriptomic explorations based on aGCTs samples are present in the literature [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Carles et al<italic>.</italic> developed an inducible FOXL2<sup>C134W</sup> stable luteinized cell line (SVOG3e) [<xref ref-type="bibr" rid="CR28">28</xref>] showing FOXL2<sup>C134W</sup> can precisely modify DNA binding specificity. More recently Weis-Banke et al. [<xref ref-type="bibr" rid="CR37">37</xref>] characterized the genome-wide binding of overexpressed FOXL2<sup>C134W</sup> and transcriptomic consequences, in presence of TGF&#x003b2; on the same non-luteinized GC cell line (HGrC1) used in our study. They showed that mutant FOXL2 has an important partner not only in SMAD3, but also in SMAD4. This corroborates our previous hypothesis that the partnership between the FOXL2<sup>C134W</sup> and TGF&#x003b2;-pathway SMADs mediators is essential and specifically orchestrates the aGCT gene expression hallmarks [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par42">Here, we carried out a novel and complementary transcriptomic investigation overexpressing FOXL2<sup>C134W</sup> in HGrC1 with its essential partner, SMAD3 [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>] to better understand its regulation and also avoiding other inevitable pleiotropic actions of the TGF&#x003b2; stimulation (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig. S1&#x02013;4). Gene Ontology (GO) analysis on the 717 DEGs (FOXL2<sup>wt</sup> vs. FOXL2<sup>C134W</sup>) revealed a clear engagement of pathways and genes related to tumorigenesis: Tissue Morphogenesis and Proliferation (MKI67, MYH9, FLNA), Regulation of the Extracellular Matrix (ECM) and Proteoglycans in Cancer (HSPG2, FLNC, COL4A2, COL5A1), Chromatin Remodeling with the Peptidyl-Lysine modification (SMARCA4, EP400, BAZ2A), downregulation of apoptotic pathway (ATF3, ATF4, CDKN2D, CXCL8), and PI3K/AKT pathway (AMIGO2, XBP1) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig S5). Although MKI67, SMARCA4 and NF-kappaB pathway components have been described in aGCTs [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR61">61</xref>&#x02013;<xref ref-type="bibr" rid="CR63">63</xref>] they have not previously been associated with FOXL2<sup>C134W</sup> or implicated as potential direct targets.</p><p id="Par43">Importantly,&#x02009;~&#x02009;40% of the 717 DEGs had a FOXL2<sup>C134W</sup> binding site at their promoters: 313 were identified using the TGF&#x003b2; treated-HGrC1 ChIP-seq [<xref ref-type="bibr" rid="CR37">37</xref>] (annotated ChIP1) and 291 using the SVOG3e ChIP-Seq [<xref ref-type="bibr" rid="CR28">28</xref>] (ChIP2). This suggests that the variations in gene expression in our system were directly related to difference in FOXL2 binding (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a, b). We considered to be important the comparison with FOXL2 ChIPseq analysis from Weis-Banke et al. (ChIP1) since it was validated with the hybrid DNA&#x02013;binding sites in RNA extracted from 4 aGCT patients and, therefore, can be easily referred to as the best <italic>bona fide</italic> enrichment for FOXL2 for the aGCT investigation in the current literature.</p><p id="Par44">Furthermore, we compared the binding sites of FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup> from Weis-Banke et al. [<xref ref-type="bibr" rid="CR37">37</xref>] and identified 12,515 sites differentially bound (q&#x02009;&#x0003c;&#x02009;0.05) by the two proteins: 10,353 had stronger FOXL2<sup>C134W</sup> signal and only 2,162 had stronger FOXL2<sup>WT</sup> signal, confirming strong gain-of-function of the mutated transcription factor. These differential sites were significantly associated with gene expression changes in our HGrC1 model overexpressing SMAD3, such as the striking examples of <italic>TGFB2</italic> and <italic>SMARCA4</italic> (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>e, overexpressed and with stronger FOXL2<sup>C134W</sup> binding), and <italic>NFKBIA</italic> (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>e, downregulated and with stronger FOXL2<sup>WT</sup> binding). We also found that these differential sites were more highly enriched at promoters of DEGs that were only regulated in FOXL2-<sup>C134W</sup> background (i.e. were not upregulated in the overexpressed FOXL2<sup>WT</sup>), suggesting that these expression changes were more likely to be due to off target binding of the mutated FOXL2 than binding to canonical sites.</p><p id="Par45">Interestingly, 11 genes&#x02013;of which 3 (TGFB2, GLI2, POLQ) are direct FOXL2 targets according previous ChIP-seq studies&#x02014;were observed to be common between the FOXL2<sup>C134W</sup> and FOXL2<sup>WT</sup> DEGs (717 genes) and the transcriptomic data from aGTC patients published by Benayon et al<italic>.</italic> [<xref ref-type="bibr" rid="CR25">25</xref>] (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>f). 90 genes have been identified in common between our study and that of Carles et al<italic>.</italic> [<xref ref-type="bibr" rid="CR28">28</xref>] (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig.&#x000a0;S8, FOXL2<sup>C134W</sup> vs Vectors condition). 29 common genes were also identified in common with the Weis-Banke et al. [<xref ref-type="bibr" rid="CR37">37</xref>] (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig. S9, FOXL2<sup>C134W</sup> vs FOXL2<sup>WT</sup>). It was remarkable that the TGBF2 gene emerges as the strongest FOXL2<sup>C134W</sup> modulated candidate since was present as target and upregulated genes in all the analysis carried out. This is consistent with the molecular relationship between FOXL2 and TGF&#x003b2; family [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Indeed, FOXL2<sup>C134W</sup> can trigger neoplastic events in granulosa cells by altering the TGF&#x003b2; pathway [<xref ref-type="bibr" rid="CR7">7</xref>]. Importantly, this finding implies that FOXL2 mutant may drive the steady induction of its key molecular SMAD partners by via a direct TGFB2 positive feedback loop. aGCT therapeutic approaches based on the inhibition of the TGF&#x003b2; family member Activin showed limited antitumoral activity. However, potentially clinically meaningful dose-related metabolic effects, including treatment of cancer cachexia, were observed that support further exploration of activin A inhibitors [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. Treatments based on the Activin inhibition and other novel TGF&#x003b2; pathway targeting approaches&#x02013;as strongly advocated by Weis-Banke et al. [<xref ref-type="bibr" rid="CR37">37</xref>] and currently optimized for other indication [<xref ref-type="bibr" rid="CR67">67</xref>&#x02013;<xref ref-type="bibr" rid="CR69">69</xref>]&#x02014;will be necessary to better determine their clinical meaning in aGCT [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. Interestingly, the chromatin remodeler SMARCA4 (BSGR1)&#x02013;already recognized as an important player in cellular tumorigenesis [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>] and expressed in all aGCT samples [<xref ref-type="bibr" rid="CR62">62</xref>]&#x02013;has been directly associated with TGF&#x003b2; pathway [<xref ref-type="bibr" rid="CR72">72</xref>] supporting the assumption of FOXL2<sup>C134W</sup> as main pathognomic orchestrator of aGCT. Our overall data are a novel contribution in deciphering how FOXL2<sup>C134W</sup> coordinates aGCT tumorigenesis.</p><p id="Par46">An important result in our study came from the transcriptomic assessment of the onco-suppressor FOXO1 effect in our system. FOXO1 is the most abundantly expressed member of FOXO gene family, and regulates vital cellular processes including the cell cycle, apoptosis, energy homeostasis and ROS catabolism [<xref ref-type="bibr" rid="CR73">73</xref>]. We previously studied the functional interaction between FOXO1, FOXL2<sup>WT</sup> and FOXL2<sup>C134W</sup> and it has been revealed the role of FOXO1 in the inhibition of CYP19 expression induced by the complex FOXL2<sup>C134W</sup>/SMAD3 [<xref ref-type="bibr" rid="CR35">35</xref>]. Interestingly, FOXO1 had no influence on FOXL2<sup>WT</sup> action, indicating that its inhibitory action targets selectively on FOXL2<sup>C134W</sup>-induced CYP19 expression in the presence of SMAD3 [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. The FOXO1 competition with FOXL2<sup>C134W</sup> in binding SMAD3 was the suggested hypothetic underlying molecular mechanism since literature has showed that FOXO1 can partner with SMAD3 in different biological occurrences [<xref ref-type="bibr" rid="CR74">74</xref>&#x02013;<xref ref-type="bibr" rid="CR77">77</xref>] and can sequestrate it from FOXL2<sup>C134W</sup> [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]. Insulin signaling through the PI3K-AKT pathway is the main modulator of FOXO1 [<xref ref-type="bibr" rid="CR79">79</xref>]. FOXO1 phosphorylation during PI3K-AKT signaling promotes its translocation from the nucleus to cytoplasm and its consequent inactivation and proteasomal degradation [<xref ref-type="bibr" rid="CR80">80</xref>]. The activation of PI3K-AKT signaling is common across many tumor types [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>] and the inactivation of FOXO1 in response to PI3K-AKT represents a common mechanism by which neoplastic cells prevent apoptosis and physiological cell cycle arrest [<xref ref-type="bibr" rid="CR83">83</xref>&#x02013;<xref ref-type="bibr" rid="CR85">85</xref>]. It is well known that AKT inhibits FOXO through direct phosphorylation [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>]. Notably, FOXO1 can be indirectly targeted via the action of AKT inhibitors [<xref ref-type="bibr" rid="CR88">88</xref>&#x02013;<xref ref-type="bibr" rid="CR91">91</xref>].</p><p id="Par47">Our data revealed that ectopic expression of FOXO1 specifically and strongly moderated the overall effect of FOXL2<sup>C134W</sup> compared to FOXL2<sup>WT</sup>, directly repressing the number of DEGs between FOXL2<sup>C134W</sup>&#x02009;+&#x02009;FOXO1 and FOXL2<sup>WT</sup> (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a, b, f). This parallels our previous findings where our data indicated the inhibitory action of FOXO1 to SMAD3/FOXL2<sup>C134W</sup> activity [<xref ref-type="bibr" rid="CR35">35</xref>]. We identified potential targets of FOXL2<sup>C134W</sup> that are significantly modulated by FOXO1 (58 genes, of which 39 in common) in the DEGs between FOXL2<sup>C134W</sup>&#x02009;+&#x02009;FOXO1 and FOXL2<sup>C134W</sup> (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c, d) confirming that FOXO1 attenuates DEGs genes that were upregulated/downregulated by FOXL2<sup>C134W</sup>. We also identified 10 targets genes annotated in both ChIP-seq analysis [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR37">37</xref>] (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>d). GO analysis of these genes (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>e) revealed FOXO1 modified similar pathways (peptidyl-lysine modification, chromatin remodeling, and ECM regulation) as those triggered by FOXL2<sup>C134W</sup>.</p></sec><sec id="Sec17"><title>Conclusions</title><p id="Par48">The comparative transcriptomic data presented in this investigation (Graphic summary depicted in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>) open new scenarios in understanding FOXL2<sup>C134W</sup> mediate regulation of cell signaling, and illustrate: (i) that FOXL2<sup>C134W</sup> can act to modulate important aGCT oncogenic pathways, including chromatin remodeling (SMARCA4, BAZ2A) and ECM regulation (HSPG2, COL4A2); (ii) the role of TGFB2, as upregulated effector and target gene in the aGCTs molecular occurrences; (iii) a potential molecular basis of emerging approaches targeting FOXO1 via AKT/PI3K pathway [<xref ref-type="bibr" rid="CR92">92</xref>&#x02013;<xref ref-type="bibr" rid="CR94">94</xref>].<fig id="Fig5"><label>Fig. 5</label><caption><p>Graphic summary of the results and conclusions. According to our results in HGrC1 cells, the complex SMAD3/FOXL2<sup>C134W</sup> drives a specific transcriptomic effect which involves genes (e.g. TGFB2, SMARCA4, BAZ2A, COL4A2 and HSPG2) related to neoplastic pathways such as Tumorigenesis, Chromatin remodeling, ECM regulation and Proteoglycans in Cancer, (top panel). FOXO1 upregulated expression obtained by Lipofection shows a significative mitigation of the SMAD3/FOXL2<sup>C134W</sup> transcriptomic effect and suggests FOXO1 transcription factor as a new putative target for the aGCTs (bottom panel)</p></caption><graphic xlink:href="12967_2021_2754_Fig5_HTML" id="MO5"/></fig></p></sec><sec sec-type="supplementary-material"><title>Supplementary Information</title><sec id="Sec18"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12967_2021_2754_MOESM1_ESM.docx"><caption><p><bold>Additional file 1: Fig. S1</bold>. FOXL2WT, FOXL2C134W and FOXO13A protein levels. After transfection with FOXL2WT, FOXL2C134W (both pCS2+ backbone) in presence/absence of FOXO13A (pCDNA3 backbone), cells were collected and lysate. (A) Immunoblot with anti-Flag tag antibody was performed to validate balanced FOXL2WT/C134W and FOXO1 protein expression. Anti &#x003b2;-Actin was used as loading control. (B) Quantification of protein levels was performed by IR fluorescence detection (Odyssey, Licor, USA) and analysis was performed with ImageJ. Fluorescence is expressed in arbitrary units.<bold> Fig. S2</bold>. RNA quality control assay. Representative diagrams of the quality control assay performed with the RNA ScreenTape&#x000ae; platform (Agilent Technology). Samples (N=3) were loaded and run. The analysis was performed with TapeStation Analysis Software (Agilent Technology). <bold>Fig. S3. </bold>PCA analysis. Scatter plot of principal components from the top 500 variable genes across the samples (A-B) or from all expressed genes (C-D), showing clustering based on transfection condition and expression of the transfected genes. Samples are color-coded based on transfection condition (1st column), FOXL2 expression (2nd column), FOXO1 expression (3rd column) and SMAD3 expression (4th column).<bold> Fig. S4</bold>. Top genes driving variability in the first 6 principal components. For PC 1 to 6, calculated on the top 500 most variable genes, we show the relative weight for each gene, ranked from highest to lowest. The top 8 genes contributing to each PC are indicated.<bold> Fig. S5. </bold>Top 50 regulated genes between FOXL2C134W and FOXL2WT ordered by p-value. (A) Heatmaps of the top 50 up-regulated genes and (B) the top 50 down-regulated genes between FOXL2C134W and FOXL2WT. The genes FOXL2 and SMAD3 were omitted form the plot. Genes are ordered by p-value (DESeq&#x0003c;0.05) and annotated for presence or absence of FOXL2C134W ChIP-seq binding site in TGF&#x003b2;-treated HGrC1 (ChIP1) [<xref ref-type="bibr" rid="CR37">37</xref>] and a FOXL2C134W ChIP-seq binding site in a SVOG3e cell line (ChIP 2) [<xref ref-type="bibr" rid="CR28">28</xref>]. For each gene, expression values were z-score normalized across samples.<bold> Fig. S6</bold>. Gene Ontology enrichment analysis of the selected subset of differentially expressed genes (DEGs) between FOXL2C134W and FOXL2WT. Gene ontology enrichment analysis in the subsets of upregulated (Cat_1, n=60, Cat_2, n=397) and downregulated (Cat_4, n=82, Cat_5, n=133) genes in which the expression in FOXL2C134W conditions was in the same (Cat_1 and Cat_4) or opposite (Cat_2 and Cat_5) direction of FOXL2WT with respect to the vector. The red line indicates p-value cutoff for p&#x0003c;0.05. Gene ontology enrichment p-values were calculated using Metascape [<xref ref-type="bibr" rid="CR51">51</xref>].<bold> Fig. S7</bold>. qPCR validation of the RNAseq expression data in TGFB1, TGFB2, ZYX, NFKBIA and SDC4 genes. Graphs show fold change means +/- s.e.m relative expression to FOXLWT following normalization to the housekeeping gene. Data were analyzed using the two-tailed unpaired t-test (*p&#x0003c;0.05, **p&#x0003c;0.01 and ***p&#x0003c;0.001).<bold> Fig. S8</bold>. Comparison with the DEGs FOXL2C134W vs Vectors from Carles et al. 2020. FOXL2C134W vs Vector DEGs were compared to previous published data at the same condition (Carles et al. 2020) [<xref ref-type="bibr" rid="CR28">28</xref>]. A) Venn diagram showing the number of differential genes (DESeq, q&#x0003c;0.05) identified in FOXL2C134W vs Vectors (939 DEGs) from the present study and from Carles et al. 2020 (471 DEGs) [<xref ref-type="bibr" rid="CR28">28</xref>]. B) Heatmaps of the top selected-50 of the total common 90 genes between FOXL2C134W and Vectors from our data and [<xref ref-type="bibr" rid="CR28">28</xref>]. Genes are annotated for presence or absence of FOXL2C134W ChIP-seq binding site in TGF&#x003b2;-treated HGrC1 (ChIP1) [<xref ref-type="bibr" rid="CR37">37</xref>] and a FOXL2C134W ChIP-seq binding site in a SVOG3e cell line (ChIP 2) [<xref ref-type="bibr" rid="CR28">28</xref>]. C) Metascape GO analysis of the 90 DEGs in both FOXL2C134W vs Vectors condition. The red line indicates p-value cutoff for p&#x0003c;0.05.<bold> Fig. S9</bold>. Comparison of the DEGs FOXL2C134W vs FOXL2WT from Weis-Banke S.E. et al. FOXL2C134W vs FOXL2WT DEGs were compared to previous published data at the same condition (Weis-Banke S.E. et al.) [<xref ref-type="bibr" rid="CR37">37</xref>]. A) Venn diagram showing the number of differential genes (DESeq, q&#x0003c;0.05) identified in FOXL2C134W vs FOXL2WT (717 DEGs) from the present study and from Weis-Banke S.E. et al. [<xref ref-type="bibr" rid="CR37">37</xref>] (537 DEGs). B) Heatmaps of the common 29 genes between FOXL2C134W and FOXL2WT from our data and [<xref ref-type="bibr" rid="CR37">37</xref>]. Genes are annotated for presence or absence of a FOXL2C134W ChIP-seq binding site in [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. C) Metascape GO analysis of the 29 DEGs in both FOXL2C134W vs FOXL2WT condition. The red line indicates p-value cutoff for p&#x0003c;0.05.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12967_2021_2754_MOESM2_ESM.zip"><caption><p><bold>Additional file 2: Table S1</bold>. List of the significant gene annotation sets. <bold>Tables S2&#x02013;S4</bold>: Genes and GO Categories.</p></caption></media></supplementary-material></p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>aGCT</term><def><p id="Par5">Adult-type granulosa cell tumor</p></def></def-item><def-item><term>DEGs</term><def><p id="Par6">Differentially expressed genes</p></def></def-item><def-item><term>DMEM-F12</term><def><p id="Par7">Dulbecco&#x02019;s modified Eagle medium &#x02013; F12</p></def></def-item><def-item><term>FOXL2</term><def><p id="Par8">Forkhead box L2</p></def></def-item><def-item><term>FOXO1</term><def><p id="Par9">Forkhead box O1</p></def></def-item><def-item><term>GC</term><def><p id="Par10">Granulosa cell</p></def></def-item><def-item><term>GCT</term><def><p id="Par11">Granulosa cell tumor</p></def></def-item><def-item><term>mRNA</term><def><p id="Par12">Messenger RNA</p></def></def-item><def-item><term>PCR</term><def><p id="Par13">Polymerase chain reaction</p></def></def-item><def-item><term>RT-PCR</term><def><p id="Par14">Quantitative reverse transcription polymerase chain reaction</p></def></def-item><def-item><term>SBE</term><def><p id="Par15">SMAD binding element</p></def></def-item><def-item><term>SEM</term><def><p id="Par16">Standard error of the mean</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Christian Secchi, Paola Benaglio equal contribution</p></fn></fn-group><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12967-021-02754-0.</p></sec><ack><title>Acknowledgements</title><p>The authors are grateful to Dr. Tomoko Nakamura and Dr. Akira Iwase for providing the HGrC1 cell line. Also, they would like to thank Dr. Louise Bilezikjian for FOXL2<sup>wt</sup> expression plasmid, Dr. Kohei Miyazono for providing us with the original hSMAD3 cDNA clones, Dr. Kristen Jepsen for the RNA-seq platform assistance and the generation of the library, Dr. Cloos for sharing BAM files of the ChIP-seq data from Weis-Banke et al<italic>.</italic>, 2020.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>CS contributed to acquisition of the data. CS, PB, FM contributed to analysis of data. CS MB and SS contributed to study conception and design. CS, PB, FM, DS, and SS contributed to the interpretation of data and manuscript preparation. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the NIH Grants R01CA244182 awarded to SS and DS, P50HD012303 awarded in part to SS, the UC San Diego Academic Senate Grant RPR378B awarded to SS and the UC San Diego Department of Obstetrics, Gynecology, and Reproductive Sciences Fund 60121B awarded to SS.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Datasets generated in this study are available through Gene Expression Omnibus accession GSE166794.</p></notes><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par50">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par51">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par52">The authors declare that they have no conflict of interest.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalfa</surname><given-names>N</given-names></name><name><surname>Veitia</surname><given-names>RA</given-names></name><name><surname>Benayoun</surname><given-names>BA</given-names></name><name><surname>Boizet-Bonhoure</surname><given-names>B</given-names></name><name><surname>Sultan</surname><given-names>C</given-names></name></person-group><article-title>The new molecular biology of granulosa cell tumors of the ovary</article-title><source>Genome Med</source><year>2009</year><volume>1</volume><issue>8</issue><fpage>81</fpage><pub-id pub-id-type="doi">10.1186/gm81</pub-id><?supplied-pmid 19725933?><pub-id pub-id-type="pmid">19725933</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khosla</surname><given-names>D</given-names></name><name><surname>Dimri</surname><given-names>K</given-names></name><name><surname>Pandey</surname><given-names>AK</given-names></name><name><surname>Mahajan</surname><given-names>R</given-names></name><name><surname>Trehan</surname><given-names>R</given-names></name></person-group><article-title>Ovarian granulosa cell tumor: clinical features, treatment, outcome, and prognostic factors</article-title><source>N Am J Med Sci</source><year>2014</year><volume>6</volume><issue>3</issue><fpage>133</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.4103/1947-2714.128475</pub-id><?supplied-pmid 24741552?><pub-id pub-id-type="pmid">24741552</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farkkila</surname><given-names>A</given-names></name><name><surname>Haltia</surname><given-names>UM</given-names></name><name><surname>Tapper</surname><given-names>J</given-names></name><name><surname>McConechy</surname><given-names>MK</given-names></name><name><surname>Huntsman</surname><given-names>DG</given-names></name><name><surname>Heikinheimo</surname><given-names>M</given-names></name></person-group><article-title>Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary</article-title><source>Ann Med</source><year>2017</year><volume>49</volume><issue>5</issue><fpage>435</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1080/07853890.2017.1294760</pub-id><?supplied-pmid 28276867?><pub-id pub-id-type="pmid">28276867</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>N</given-names></name><name><surname>Parma</surname><given-names>G</given-names></name><name><surname>Zanagnolo</surname><given-names>V</given-names></name><name><surname>Insinga</surname><given-names>A</given-names></name></person-group><article-title>Management of ovarian stromal cell tumors</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><issue>20</issue><fpage>2944</fpage><lpage>2951</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.11.1005</pub-id><?supplied-pmid 17617526?><pub-id pub-id-type="pmid">17617526</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>LA</given-names></name><name><surname>Okagaki</surname><given-names>T</given-names></name><name><surname>Gallup</surname><given-names>DG</given-names></name><name><surname>Twiggs</surname><given-names>LB</given-names></name><name><surname>Messing</surname><given-names>MJ</given-names></name><name><surname>Carson</surname><given-names>LF</given-names></name></person-group><article-title>Mitotic count, nuclear atypia, and immunohistochemical determination of Ki-67, c-myc, p21-ras, c-erbB2, and p53 expression in granulosa cell tumors of the ovary: mitotic count and Ki-67 are indicators of poor prognosis</article-title><source>Gynecol Oncol</source><year>1996</year><volume>61</volume><issue>2</issue><fpage>227</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1006/gyno.1996.0130</pub-id><?supplied-pmid 8626138?><pub-id pub-id-type="pmid">8626138</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amsterdam</surname><given-names>A</given-names></name><name><surname>Selvaraj</surname><given-names>N</given-names></name></person-group><article-title>Control of differentiation, transformation, and apoptosis in granulosa cells by oncogenes, oncoviruses, and tumor suppressor genes</article-title><source>Endocr Rev</source><year>1997</year><volume>18</volume><issue>4</issue><fpage>435</fpage><lpage>461</lpage><?supplied-pmid 9267759?><pub-id pub-id-type="pmid">9267759</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>DTH</given-names></name><name><surname>Fuller</surname><given-names>PJ</given-names></name><name><surname>Chu</surname><given-names>S</given-names></name></person-group><article-title>Impact of FOXL2 mutations on signaling in ovarian granulosa cell tumors</article-title><source>Int J Biochem Cell Biol</source><year>2016</year><volume>72</volume><fpage>51</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2016.01.003</pub-id><?supplied-pmid 26791928?><pub-id pub-id-type="pmid">26791928</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>SP</given-names></name><name><surname>Kobel</surname><given-names>M</given-names></name><name><surname>Senz</surname><given-names>J</given-names></name><name><surname>Morin</surname><given-names>RD</given-names></name><name><surname>Clarke</surname><given-names>BA</given-names></name><name><surname>Wiegand</surname><given-names>KC</given-names></name><name><surname>Leung</surname><given-names>G</given-names></name><name><surname>Zayed</surname><given-names>A</given-names></name><name><surname>Mehl</surname><given-names>E</given-names></name><name><surname>Kalloger</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Mutation of FOXL2 in granulosa-cell tumors of the ovary</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><issue>26</issue><fpage>2719</fpage><lpage>2729</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0902542</pub-id><?supplied-pmid 19516027?><pub-id pub-id-type="pmid">19516027</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benayoun</surname><given-names>BA</given-names></name><name><surname>Caburet</surname><given-names>S</given-names></name><name><surname>Dipietromaria</surname><given-names>A</given-names></name><name><surname>Georges</surname><given-names>A</given-names></name><name><surname>D'Haene</surname><given-names>B</given-names></name><name><surname>Pandaranayaka</surname><given-names>PJ</given-names></name><name><surname>L'Hote</surname><given-names>D</given-names></name><name><surname>Todeschini</surname><given-names>AL</given-names></name><name><surname>Krishnaswamy</surname><given-names>S</given-names></name><name><surname>Fellous</surname><given-names>M</given-names></name><etal/></person-group><article-title>Functional exploration of the adult ovarian granulosa cell tumor-associated somatic FOXL2 mutation p.Cys134Trp (c.402C&#x0003e;G)</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><issue>1</issue><fpage>e8789</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0008789</pub-id><?supplied-pmid 20098707?><pub-id pub-id-type="pmid">20098707</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>NI</given-names></name><name><surname>Knower</surname><given-names>KC</given-names></name><name><surname>Lazarus</surname><given-names>KA</given-names></name><name><surname>Fuller</surname><given-names>PJ</given-names></name><name><surname>Simpson</surname><given-names>ER</given-names></name><name><surname>Clyne</surname><given-names>CD</given-names></name></person-group><article-title>Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><issue>12</issue><fpage>e14389</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0014389</pub-id><?supplied-pmid 21188138?><pub-id pub-id-type="pmid">21188138</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anttonen</surname><given-names>M</given-names></name><name><surname>Pihlajoki</surname><given-names>M</given-names></name><name><surname>Andersson</surname><given-names>N</given-names></name><name><surname>Georges</surname><given-names>A</given-names></name><name><surname>L'Hote</surname><given-names>D</given-names></name><name><surname>Vattulainen</surname><given-names>S</given-names></name><name><surname>Farkkila</surname><given-names>A</given-names></name><name><surname>Unkila-Kallio</surname><given-names>L</given-names></name><name><surname>Veitia</surname><given-names>RA</given-names></name><name><surname>Heikinheimo</surname><given-names>M</given-names></name></person-group><article-title>FOXL2, GATA4, and SMAD3 co-operatively modulate gene expression, cell viability and apoptosis in ovarian granulosa cell tumor cells</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><issue>1</issue><fpage>e85545</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0085545</pub-id><?supplied-pmid 24416423?><pub-id pub-id-type="pmid">24416423</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Kim</surname><given-names>HM</given-names></name><name><surname>Park</surname><given-names>HO</given-names></name><name><surname>Ha</surname><given-names>NC</given-names></name><name><surname>Kim</surname><given-names>TH</given-names></name><name><surname>Park</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Bae</surname><given-names>J</given-names></name></person-group><article-title>FOXL2 posttranslational modifications mediated by GSK3beta determine the growth of granulosa cell tumours</article-title><source>Nat Commun</source><year>2014</year><volume>5</volume><fpage>2936</fpage><pub-id pub-id-type="doi">10.1038/ncomms3936</pub-id><?supplied-pmid 24390485?><pub-id pub-id-type="pmid">24390485</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caburet</surname><given-names>S</given-names></name><name><surname>Anttonen</surname><given-names>M</given-names></name><name><surname>Todeschini</surname><given-names>AL</given-names></name><name><surname>Unkila-Kallio</surname><given-names>L</given-names></name><name><surname>Mestivier</surname><given-names>D</given-names></name><name><surname>Butzow</surname><given-names>R</given-names></name><name><surname>Veitia</surname><given-names>RA</given-names></name></person-group><article-title>Combined comparative genomic hybridization and transcriptomic analyses of ovarian granulosa cell tumors point to novel candidate driver genes</article-title><source>BMC Cancer</source><year>2015</year><volume>15</volume><fpage>251</fpage><pub-id pub-id-type="doi">10.1186/s12885-015-1283-0</pub-id><?supplied-pmid 25884336?><pub-id pub-id-type="pmid">25884336</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamieson</surname><given-names>S</given-names></name><name><surname>Fuller</surname><given-names>PJ</given-names></name></person-group><article-title>Molecular pathogenesis of granulosa cell tumors of the ovary</article-title><source>Endocr Rev</source><year>2012</year><volume>33</volume><issue>1</issue><fpage>109</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1210/er.2011-0014</pub-id><?supplied-pmid 22240241?><pub-id pub-id-type="pmid">22240241</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlenhaut</surname><given-names>NH</given-names></name><name><surname>Treier</surname><given-names>M</given-names></name></person-group><article-title>Forkhead transcription factors in ovarian function</article-title><source>Reproduction</source><year>2011</year><volume>142</volume><issue>4</issue><fpage>489</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1530/REP-11-0092</pub-id><?supplied-pmid 21810859?><pub-id pub-id-type="pmid">21810859</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golson</surname><given-names>ML</given-names></name><name><surname>Kaestner</surname><given-names>KH</given-names></name></person-group><article-title>Fox transcription factors: from development to disease</article-title><source>Development</source><year>2016</year><volume>143</volume><issue>24</issue><fpage>4558</fpage><lpage>4570</lpage><pub-id pub-id-type="doi">10.1242/dev.112672</pub-id><?supplied-pmid 5201025?><pub-id pub-id-type="pmid">27965437</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ottolenghi</surname><given-names>C</given-names></name><name><surname>Omari</surname><given-names>S</given-names></name><name><surname>Garcia-Ortiz</surname><given-names>JE</given-names></name><name><surname>Uda</surname><given-names>M</given-names></name><name><surname>Crisponi</surname><given-names>L</given-names></name><name><surname>Forabosco</surname><given-names>A</given-names></name><name><surname>Pilia</surname><given-names>G</given-names></name><name><surname>Schlessinger</surname><given-names>D</given-names></name></person-group><article-title>Foxl2 is required for commitment to ovary differentiation</article-title><source>Hum Mol Genet</source><year>2005</year><volume>14</volume><issue>14</issue><fpage>2053</fpage><lpage>2062</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddi210</pub-id><?supplied-pmid 15944199?><pub-id pub-id-type="pmid">15944199</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batista</surname><given-names>F</given-names></name><name><surname>Vaiman</surname><given-names>D</given-names></name><name><surname>Dausset</surname><given-names>J</given-names></name><name><surname>Fellous</surname><given-names>M</given-names></name><name><surname>Veitia</surname><given-names>RA</given-names></name></person-group><article-title>Potential targets of FOXL2, a transcription factor involved in craniofacial and follicular development, identified by transcriptomics</article-title><source>Proc Natl Acad Sci USA</source><year>2007</year><volume>104</volume><issue>9</issue><fpage>3330</fpage><lpage>3335</lpage><pub-id pub-id-type="doi">10.1073/pnas.0611326104</pub-id><?supplied-pmid 17360647?><pub-id pub-id-type="pmid">17360647</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benayoun</surname><given-names>BA</given-names></name><name><surname>Batista</surname><given-names>F</given-names></name><name><surname>Auer</surname><given-names>J</given-names></name><name><surname>Dipietromaria</surname><given-names>A</given-names></name><name><surname>L'Hote</surname><given-names>D</given-names></name><name><surname>De Baere</surname><given-names>E</given-names></name><name><surname>Veitia</surname><given-names>RA</given-names></name></person-group><article-title>Positive and negative feedback regulates the transcription factor FOXL2 in response to cell stress: evidence for a regulatory imbalance induced by disease-causing mutations</article-title><source>Hum Mol Genet</source><year>2009</year><volume>18</volume><issue>4</issue><fpage>632</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddn389</pub-id><?supplied-pmid 19010791?><pub-id pub-id-type="pmid">19010791</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moumne</surname><given-names>L</given-names></name><name><surname>Batista</surname><given-names>F</given-names></name><name><surname>Benayoun</surname><given-names>BA</given-names></name><name><surname>Nallathambi</surname><given-names>J</given-names></name><name><surname>Fellous</surname><given-names>M</given-names></name><name><surname>Sundaresan</surname><given-names>P</given-names></name><name><surname>Veitia</surname><given-names>RA</given-names></name></person-group><article-title>The mutations and potential targets of the forkhead transcription factor FOXL2</article-title><source>Mol Cell Endocrinol</source><year>2008</year><volume>282</volume><issue>1&#x02013;2</issue><fpage>2</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2007.11.006</pub-id><?supplied-pmid 18155828?><pub-id pub-id-type="pmid">18155828</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marongiu</surname><given-names>M</given-names></name><name><surname>Deiana</surname><given-names>M</given-names></name><name><surname>Marcia</surname><given-names>L</given-names></name><name><surname>Sbardellati</surname><given-names>A</given-names></name><name><surname>Asunis</surname><given-names>I</given-names></name><name><surname>Meloni</surname><given-names>A</given-names></name><name><surname>Angius</surname><given-names>A</given-names></name><name><surname>Cusano</surname><given-names>R</given-names></name><name><surname>Loi</surname><given-names>A</given-names></name><name><surname>Crobu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Novel action of FOXL2 as mediator of Col1a2 gene autoregulation</article-title><source>Dev Biol</source><year>2016</year><volume>416</volume><issue>1</issue><fpage>200</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2016.05.022</pub-id><?supplied-pmid 27212026?><pub-id pub-id-type="pmid">27212026</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marongiu</surname><given-names>M</given-names></name><name><surname>Marcia</surname><given-names>L</given-names></name><name><surname>Pelosi</surname><given-names>E</given-names></name><name><surname>Lovicu</surname><given-names>M</given-names></name><name><surname>Deiana</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Puddu</surname><given-names>A</given-names></name><name><surname>Loi</surname><given-names>A</given-names></name><name><surname>Uda</surname><given-names>M</given-names></name><name><surname>Forabosco</surname><given-names>A</given-names></name><etal/></person-group><article-title>FOXL2 modulates cartilage, skeletal development and IGF1-dependent growth in mice</article-title><source>BMC Dev Biol</source><year>2015</year><volume>15</volume><fpage>27</fpage><pub-id pub-id-type="doi">10.1186/s12861-015-0072-y</pub-id><?supplied-pmid 26134413?><pub-id pub-id-type="pmid">26134413</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicol</surname><given-names>B</given-names></name><name><surname>Grimm</surname><given-names>SA</given-names></name><name><surname>Gruzdev</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>GJ</given-names></name><name><surname>Ray</surname><given-names>MK</given-names></name><name><surname>Yao</surname><given-names>HH</given-names></name></person-group><article-title>Genome-wide identification of FOXL2 binding and characterization of FOXL2 feminizing action in the fetal gonads</article-title><source>Hum Mol Genet</source><year>2018</year><volume>27</volume><issue>24</issue><fpage>4273</fpage><lpage>4287</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddy312</pub-id><?supplied-pmid 30212841?><pub-id pub-id-type="pmid">30212841</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benayoun</surname><given-names>BA</given-names></name><name><surname>Georges</surname><given-names>AB</given-names></name><name><surname>L'Hote</surname><given-names>D</given-names></name><name><surname>Andersson</surname><given-names>N</given-names></name><name><surname>Dipietromaria</surname><given-names>A</given-names></name><name><surname>Todeschini</surname><given-names>AL</given-names></name><name><surname>Caburet</surname><given-names>S</given-names></name><name><surname>Bazin</surname><given-names>C</given-names></name><name><surname>Anttonen</surname><given-names>M</given-names></name><name><surname>Veitia</surname><given-names>RA</given-names></name></person-group><article-title>Transcription factor FOXL2 protects granulosa cells from stress and delays cell cycle: role of its regulation by the SIRT1 deacetylase</article-title><source>Hum Mol Genet</source><year>2011</year><volume>20</volume><issue>9</issue><fpage>1673</fpage><lpage>1686</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddr042</pub-id><?supplied-pmid 21289058?><pub-id pub-id-type="pmid">21289058</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benayoun</surname><given-names>BA</given-names></name><name><surname>Anttonen</surname><given-names>M</given-names></name><name><surname>L'Hote</surname><given-names>D</given-names></name><name><surname>Bailly-Bechet</surname><given-names>M</given-names></name><name><surname>Andersson</surname><given-names>N</given-names></name><name><surname>Heikinheimo</surname><given-names>M</given-names></name><name><surname>Veitia</surname><given-names>RA</given-names></name></person-group><article-title>Adult ovarian granulosa cell tumor transcriptomics: prevalence of FOXL2 target genes misregulation gives insights into the pathogenic mechanism of the p.Cys134Trp somatic mutation</article-title><source>Oncogene</source><year>2013</year><volume>32</volume><issue>22</issue><fpage>2739</fpage><lpage>2746</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.298</pub-id><?supplied-pmid 22797072?><pub-id pub-id-type="pmid">22797072</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexiadis</surname><given-names>M</given-names></name><name><surname>Chu</surname><given-names>S</given-names></name><name><surname>Leung</surname><given-names>D</given-names></name><name><surname>Gould</surname><given-names>JA</given-names></name><name><surname>Jobling</surname><given-names>T</given-names></name><name><surname>Fuller</surname><given-names>PJ</given-names></name></person-group><article-title>Transcriptomic analysis of stage 1 versus advanced adult granulosa cell tumors</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><issue>12</issue><fpage>14207</fpage><lpage>14219</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.7422</pub-id><?supplied-pmid 26893359?><pub-id pub-id-type="pmid">26893359</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roze</surname><given-names>J</given-names></name><name><surname>Monroe</surname><given-names>G</given-names></name><name><surname>Kutzera</surname><given-names>J</given-names></name><name><surname>Groeneweg</surname><given-names>J</given-names></name><name><surname>Stelloo</surname><given-names>E</given-names></name><name><surname>Paijens</surname><given-names>S</given-names></name><name><surname>Nijman</surname><given-names>H</given-names></name><name><surname>Meurs</surname><given-names>HV</given-names></name><name><surname>Lonkhuijzen</surname><given-names>LV</given-names></name><name><surname>Piek</surname><given-names>J</given-names></name><etal/></person-group><article-title>Whole genome analysis of ovarian granulosa cell tumors reveals tumor heterogeneity and a high-grade TP53-Specific Subgroup</article-title><source>Cancers</source><year>2020</year><volume>12</volume><issue>5</issue><fpage>1308</fpage><pub-id pub-id-type="doi">10.3390/cancers12051308</pub-id><?supplied-pmid 7281495?><pub-id pub-id-type="pmid">7281495</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carles</surname><given-names>A</given-names></name><name><surname>Trigo-Gonzalez</surname><given-names>G</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Cheng</surname><given-names>SG</given-names></name><name><surname>Moksa</surname><given-names>M</given-names></name><name><surname>Bilenky</surname><given-names>M</given-names></name><name><surname>Huntsman</surname><given-names>DG</given-names></name><name><surname>Morin</surname><given-names>GB</given-names></name><name><surname>Hirst</surname><given-names>M</given-names></name></person-group><article-title>The pathognomonic FOXL2 C134W mutation alters DNA binding specificity</article-title><source>Cancer Res</source><year>2020</year><volume>80</volume><fpage>3480</fpage><lpage>3491</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-20-0104</pub-id><?supplied-pmid 32641414?><pub-id pub-id-type="pmid">32641414</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blount</surname><given-names>AL</given-names></name><name><surname>Schmidt</surname><given-names>K</given-names></name><name><surname>Justice</surname><given-names>NJ</given-names></name><name><surname>Vale</surname><given-names>WW</given-names></name><name><surname>Fischer</surname><given-names>WH</given-names></name><name><surname>Bilezikjian</surname><given-names>LM</given-names></name></person-group><article-title>FoxL2 and Smad3 coordinately regulate follistatin gene transcription</article-title><source>J Biol Chem</source><year>2009</year><volume>284</volume><issue>12</issue><fpage>7631</fpage><lpage>7645</lpage><pub-id pub-id-type="doi">10.1074/jbc.M806676200</pub-id><?supplied-pmid 19106105?><pub-id pub-id-type="pmid">19106105</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>S</given-names></name><name><surname>Lamba</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Bernard</surname><given-names>DJ</given-names></name></person-group><article-title>SMADs and FOXL2 synergistically regulate murine FSHbeta transcription via a conserved proximal promoter element</article-title><source>Mol Endocrinol</source><year>2011</year><volume>25</volume><issue>7</issue><fpage>1170</fpage><lpage>1183</lpage><pub-id pub-id-type="doi">10.1210/me.2010-0480</pub-id><?supplied-pmid 21622537?><pub-id pub-id-type="pmid">21622537</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corpuz</surname><given-names>PS</given-names></name><name><surname>Lindaman</surname><given-names>LL</given-names></name><name><surname>Mellon</surname><given-names>PL</given-names></name><name><surname>Coss</surname><given-names>D</given-names></name></person-group><article-title>FoxL2 Is required for activin induction of the mouse and human follicle-stimulating hormone beta-subunit genes</article-title><source>Mol Endocrinol</source><year>2010</year><volume>24</volume><issue>5</issue><fpage>1037</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1210/me.2009-0425</pub-id><?supplied-pmid 20233786?><pub-id pub-id-type="pmid">20233786</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coss</surname><given-names>D</given-names></name><name><surname>Mellon</surname><given-names>PL</given-names></name><name><surname>Thackray</surname><given-names>VG</given-names></name></person-group><article-title>A FoxL in the Smad house: activin regulation of FSH</article-title><source>Trends Endocrinol Metab</source><year>2010</year><volume>21</volume><issue>9</issue><fpage>562</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2010.05.006</pub-id><?supplied-pmid 20598900?><pub-id pub-id-type="pmid">20598900</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nonis</surname><given-names>D</given-names></name><name><surname>McTavish</surname><given-names>KJ</given-names></name><name><surname>Shimasaki</surname><given-names>S</given-names></name></person-group><article-title>Essential but differential role of FOXL2wt and FOXL2C134W in GDF-9 stimulation of follistatin transcription in co-operation with Smad3 in the human granulosa cell line COV434</article-title><source>Mol Cell Endocrinol</source><year>2013</year><volume>372</volume><issue>1&#x02013;2</issue><fpage>42</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2013.02.020</pub-id><?supplied-pmid 23523567?><pub-id pub-id-type="pmid">23523567</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belli</surname><given-names>M</given-names></name><name><surname>Iwata</surname><given-names>N</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Iwase</surname><given-names>A</given-names></name><name><surname>Stupack</surname><given-names>D</given-names></name><name><surname>Shimasaki</surname><given-names>S</given-names></name></person-group><article-title>FOXL2C134W-induced cyp19 expression via cooperation With SMAD3 in HGrC1 Cells</article-title><source>Endocrinology</source><year>2018</year><volume>159</volume><issue>4</issue><fpage>1690</fpage><lpage>1703</lpage><pub-id pub-id-type="doi">10.1210/en.2017-03207</pub-id><?supplied-pmid 29471425?><pub-id pub-id-type="pmid">29471425</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belli</surname><given-names>M</given-names></name><name><surname>Secchi</surname><given-names>C</given-names></name><name><surname>Stupack</surname><given-names>D</given-names></name><name><surname>Shimasaki</surname><given-names>S</given-names></name></person-group><article-title>FOXO1 negates the cooperative action of FOXL2(C134W) and SMAD3 in CYP19 expression in HGrC1 Cells by sequestering SMAD3</article-title><source>J Endocr Soc</source><year>2019</year><volume>3</volume><issue>11</issue><fpage>2064</fpage><lpage>2081</lpage><pub-id pub-id-type="doi">10.1210/js.2019-00279</pub-id><?supplied-pmid 31701078?><pub-id pub-id-type="pmid">31701078</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Odle</surname><given-names>AK</given-names></name><name><surname>Childs</surname><given-names>GV</given-names></name></person-group><article-title>SMAD-FOXL2 regulation of FSHB: a game of human and mouse</article-title><source>Endocrinology</source><year>2020</year><volume>161</volume><issue>7</issue><fpage>bqaa077</fpage><pub-id pub-id-type="doi">10.1210/endocr/bqaa077</pub-id><?supplied-pmid 32422656?><pub-id pub-id-type="pmid">32422656</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weis-Banke</surname><given-names>SE</given-names></name><name><surname>Lerdrup</surname><given-names>M</given-names></name><name><surname>Kleine-Kohlbrecher</surname><given-names>D</given-names></name><name><surname>Mohammad</surname><given-names>F</given-names></name><name><surname>Sidoli</surname><given-names>S</given-names></name><name><surname>Jensen</surname><given-names>ON</given-names></name><name><surname>Yanase</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Iwase</surname><given-names>A</given-names></name><name><surname>Stylianou</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mutant FOXL2(C134W) Hijacks SMAD4 and SMAD2/3 to drive adult granulosa cell tumors</article-title><source>Cancer Res</source><year>2020</year><volume>80</volume><issue>17</issue><fpage>3466</fpage><lpage>3479</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-20-0259</pub-id><?supplied-pmid 32641411?><pub-id pub-id-type="pmid">32641411</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massague</surname><given-names>J</given-names></name></person-group><article-title>TGFbeta signalling in context</article-title><source>Nat Rev Mol Cell Biol</source><year>2012</year><volume>13</volume><issue>10</issue><fpage>616</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1038/nrm3434</pub-id><?supplied-pmid 22992590?><pub-id pub-id-type="pmid">22992590</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derynck</surname><given-names>R</given-names></name><name><surname>Budi</surname><given-names>EH</given-names></name></person-group><article-title>Specificity, versatility, and control of TGF-beta family signaling</article-title><source>Sci Signal</source><year>2019</year><volume>12</volume><issue>570</issue><fpage>eaav5183</fpage><pub-id pub-id-type="doi">10.1126/scisignal.aav5183</pub-id><?supplied-pmid 30808818?><pub-id pub-id-type="pmid">30808818</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farhan</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Gaur</surname><given-names>U</given-names></name><name><surname>Little</surname><given-names>PJ</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name></person-group><article-title>FOXO signaling pathways as therapeutic targets in cancer</article-title><source>Int J Biol Sci</source><year>2017</year><volume>13</volume><issue>7</issue><fpage>815</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.7150/ijbs.20052</pub-id><?supplied-pmid 28808415?><pub-id pub-id-type="pmid">28808415</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McTavish</surname><given-names>KJ</given-names></name><name><surname>Nonis</surname><given-names>D</given-names></name><name><surname>Hoang</surname><given-names>YD</given-names></name><name><surname>Shimasaki</surname><given-names>S</given-names></name></person-group><article-title>Granulosa cell tumor mutant FOXL2C134W suppresses GDF-9 and activin A-induced follistatin transcription in primary granulosa cells</article-title><source>Mol Cell Endocrinol</source><year>2013</year><volume>372</volume><issue>1&#x02013;2</issue><fpage>57</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2013.03.021</pub-id><?supplied-pmid 23567549?><pub-id pub-id-type="pmid">23567549</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawabata</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Hanyu</surname><given-names>A</given-names></name><name><surname>Imamura</surname><given-names>T</given-names></name><name><surname>Miyazono</surname><given-names>K</given-names></name></person-group><article-title>Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors</article-title><source>EMBO J</source><year>1998</year><volume>17</volume><issue>14</issue><fpage>4056</fpage><lpage>4065</lpage><pub-id pub-id-type="doi">10.1093/emboj/17.14.4056</pub-id><?supplied-pmid 9670020?><pub-id pub-id-type="pmid">9670020</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwase</surname><given-names>AB</given-names></name><name><surname>Kiyono</surname><given-names>T</given-names></name><name><surname>Takikawa</surname><given-names>S</given-names></name><name><surname>Goto</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Nagatomo</surname><given-names>Y</given-names></name><name><surname>Nakahara</surname><given-names>T</given-names></name><name><surname>Kotani</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Establishment of a human nonluteinized granulosa cell line that transitions from the gonadotropin-independent to the gonadotropin-dependent status</article-title><source>Endocrinology</source><year>2012</year><volume>153</volume><issue>6</issue><fpage>2851</fpage><lpage>2860</lpage><pub-id pub-id-type="doi">10.1210/en.2011-1810</pub-id><?supplied-pmid 22467494?><pub-id pub-id-type="pmid">22467494</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finotello</surname><given-names>F</given-names></name><name><surname>Di Camillo</surname><given-names>B</given-names></name></person-group><article-title>Measuring differential gene expression with RNA-seq: challenges and strategies for data analysis</article-title><source>Brief Funct Genomics</source><year>2015</year><volume>14</volume><issue>2</issue><fpage>130</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1093/bfgp/elu035</pub-id><?supplied-pmid 25240000?><pub-id pub-id-type="pmid">25240000</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patro</surname><given-names>R</given-names></name><name><surname>Duggal</surname><given-names>G</given-names></name><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Kingsford</surname><given-names>C</given-names></name></person-group><article-title>Salmon provides fast and bias-aware quantification of transcript expression</article-title><source>Nat Methods</source><year>2017</year><volume>14</volume><issue>4</issue><fpage>417</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4197</pub-id><?supplied-pmid 28263959?><pub-id pub-id-type="pmid">28263959</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soneson</surname><given-names>C</given-names></name><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Robinson</surname><given-names>MD</given-names></name></person-group><article-title>Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences</article-title><source>F1000Res</source><year>2015</year><volume>4</volume><fpage>1521</fpage><pub-id pub-id-type="doi">10.12688/f1000research.7563.1</pub-id><?supplied-pmid 26925227?><pub-id pub-id-type="pmid">26925227</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol</source><year>2014</year><volume>15</volume><issue>12</issue><fpage>550</fpage><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><?supplied-pmid 25516281?><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Meyer</surname><given-names>CA</given-names></name><name><surname>Eeckhoute</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>DS</given-names></name><name><surname>Bernstein</surname><given-names>BE</given-names></name><name><surname>Nusbaum</surname><given-names>C</given-names></name><name><surname>Myers</surname><given-names>RM</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><etal/></person-group><article-title>Model-based analysis of ChIP-Seq (MACS)</article-title><source>Genome Biol</source><year>2008</year><volume>9</volume><issue>9</issue><fpage>R137</fpage><pub-id pub-id-type="doi">10.1186/gb-2008-9-9-r137</pub-id><?supplied-pmid 2592715?><pub-id pub-id-type="pmid">18798982</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langmead</surname><given-names>B</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><article-title>Fast gapped-read alignment with Bowtie 2</article-title><source>Nat Methods</source><year>2012</year><volume>9</volume><issue>4</issue><fpage>357</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1923</pub-id><?supplied-pmid 3322381?><pub-id pub-id-type="pmid">22388286</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics</source><year>2014</year><volume>30</volume><issue>7</issue><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt656</pub-id><?supplied-pmid 24227677?><pub-id pub-id-type="pmid">24227677</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Pache</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Khodabakhshi</surname><given-names>AH</given-names></name><name><surname>Tanaseichuk</surname><given-names>O</given-names></name><name><surname>Benner</surname><given-names>C</given-names></name><name><surname>Chanda</surname><given-names>SK</given-names></name></person-group><article-title>Metascape provides a biologist-oriented resource for the analysis of systems-level datasets</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><issue>1</issue><fpage>1523</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-09234-6</pub-id><?supplied-pmid 6447622?><pub-id pub-id-type="pmid">30944313</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauh-Hain</surname><given-names>JA</given-names></name><name><surname>Krivak</surname><given-names>TC</given-names></name><name><surname>Del Carmen</surname><given-names>MG</given-names></name><name><surname>Olawaiye</surname><given-names>AB</given-names></name></person-group><article-title>Ovarian cancer screening and early detection in the general population</article-title><source>Rev Obstet Gynecol</source><year>2011</year><volume>4</volume><issue>1</issue><fpage>15</fpage><lpage>21</lpage><?supplied-pmid 21629494?><pub-id pub-id-type="pmid">21629494</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schumer</surname><given-names>ST</given-names></name><name><surname>Cannistra</surname><given-names>SA</given-names></name></person-group><article-title>Granulosa cell tumor of the ovary</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><issue>6</issue><fpage>1180</fpage><lpage>1189</lpage><pub-id pub-id-type="doi">10.1200/JCO.2003.10.019</pub-id><?supplied-pmid 12637488?><pub-id pub-id-type="pmid">12637488</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalfa</surname><given-names>N</given-names></name><name><surname>Philibert</surname><given-names>P</given-names></name><name><surname>Patte</surname><given-names>C</given-names></name><name><surname>Thibaud</surname><given-names>E</given-names></name><name><surname>Pienkowski</surname><given-names>C</given-names></name><name><surname>Ecochard</surname><given-names>A</given-names></name><name><surname>Boizet-Bonhoure</surname><given-names>B</given-names></name><name><surname>Fellous</surname><given-names>M</given-names></name><name><surname>Sultan</surname><given-names>C</given-names></name></person-group><article-title>Juvenile granulosa-cell tumor: clinical and molecular expression</article-title><source>Gynecol Obstet Fertil</source><year>2009</year><volume>37</volume><issue>1</issue><fpage>33</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.gyobfe.2008.06.026</pub-id><?supplied-pmid 19119048?><pub-id pub-id-type="pmid">19119048</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haltia</surname><given-names>UM</given-names></name><name><surname>Pihlajoki</surname><given-names>M</given-names></name><name><surname>Andersson</surname><given-names>N</given-names></name><name><surname>Makinen</surname><given-names>L</given-names></name><name><surname>Tapper</surname><given-names>J</given-names></name><name><surname>Cervera</surname><given-names>A</given-names></name><name><surname>Horlings</surname><given-names>HM</given-names></name><name><surname>Turpeinen</surname><given-names>U</given-names></name><name><surname>Anttonen</surname><given-names>M</given-names></name><name><surname>Butzow</surname><given-names>R</given-names></name><etal/></person-group><article-title>Functional profiling of FSH and estradiol in ovarian granulosa cell tumors</article-title><source>J Endocr Soc</source><year>2020</year><volume>4</volume><issue>4</issue><fpage>bvaa034</fpage><pub-id pub-id-type="doi">10.1210/jendso/bvaa034</pub-id><?supplied-pmid 32309755?><pub-id pub-id-type="pmid">32309755</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamieson</surname><given-names>S</given-names></name><name><surname>Butzow</surname><given-names>R</given-names></name><name><surname>Andersson</surname><given-names>N</given-names></name><name><surname>Alexiadis</surname><given-names>M</given-names></name><name><surname>Unkila-Kallio</surname><given-names>L</given-names></name><name><surname>Heikinheimo</surname><given-names>M</given-names></name><name><surname>Fuller</surname><given-names>PJ</given-names></name><name><surname>Anttonen</surname><given-names>M</given-names></name></person-group><article-title>The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary</article-title><source>Mod Pathol</source><year>2010</year><volume>23</volume><issue>11</issue><fpage>1477</fpage><lpage>1485</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2010.145</pub-id><?supplied-pmid 20693978?><pub-id pub-id-type="pmid">20693978</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zannoni</surname><given-names>GF</given-names></name><name><surname>Improta</surname><given-names>G</given-names></name><name><surname>Petrillo</surname><given-names>M</given-names></name><name><surname>Pettinato</surname><given-names>A</given-names></name><name><surname>Scambia</surname><given-names>G</given-names></name><name><surname>Fraggetta</surname><given-names>F</given-names></name></person-group><article-title>FOXL2 molecular status in adult granulosa cell tumors of the ovary: a study of primary and metastatic cases</article-title><source>Oncol Lett</source><year>2016</year><volume>12</volume><issue>2</issue><fpage>1159</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.3892/ol.2016.4711</pub-id><?supplied-pmid 27446412?><pub-id pub-id-type="pmid">27446412</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caburet</surname><given-names>S</given-names></name><name><surname>Georges</surname><given-names>A</given-names></name><name><surname>L'Hote</surname><given-names>D</given-names></name><name><surname>Todeschini</surname><given-names>AL</given-names></name><name><surname>Benayoun</surname><given-names>BA</given-names></name><name><surname>Veitia</surname><given-names>RA</given-names></name></person-group><article-title>The transcription factor FOXL2: at the crossroads of ovarian physiology and pathology</article-title><source>Mol Cell Endocrinol</source><year>2012</year><volume>356</volume><issue>1&#x02013;2</issue><fpage>55</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2011.06.019</pub-id><?supplied-pmid 21763750?><pub-id pub-id-type="pmid">21763750</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Bao</surname><given-names>R</given-names></name><name><surname>Peng</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name></person-group><article-title>The molecular mechanism of ovarian granulosa cell tumors</article-title><source>J Ovarian Res</source><year>2018</year><volume>11</volume><issue>1</issue><fpage>13</fpage><pub-id pub-id-type="doi">10.1186/s13048-018-0384-1</pub-id><?supplied-pmid 29409506?><pub-id pub-id-type="pmid">29409506</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kommoss</surname><given-names>S</given-names></name><name><surname>Gilks</surname><given-names>CB</given-names></name><name><surname>Penzel</surname><given-names>R</given-names></name><name><surname>Herpel</surname><given-names>E</given-names></name><name><surname>Mackenzie</surname><given-names>R</given-names></name><name><surname>Huntsman</surname><given-names>D</given-names></name><name><surname>Schirmacher</surname><given-names>P</given-names></name><name><surname>Anglesio</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>D</given-names></name><name><surname>Kommoss</surname><given-names>F</given-names></name></person-group><article-title>A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary</article-title><source>Histopathology</source><year>2014</year><volume>64</volume><issue>3</issue><fpage>380</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1111/his.12253</pub-id><?supplied-pmid 24192202?><pub-id pub-id-type="pmid">24192202</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guleria</surname><given-names>P</given-names></name><name><surname>Kumar</surname><given-names>L</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Bhatla</surname><given-names>N</given-names></name><name><surname>Ray</surname><given-names>R</given-names></name><name><surname>Singhal</surname><given-names>S</given-names></name><name><surname>Meena</surname><given-names>J</given-names></name><name><surname>Mathur</surname><given-names>SR</given-names></name></person-group><article-title>A clinicopathological study of granulosa cell tumors of the ovary: can morphology predict prognosis?</article-title><source>Indian J Pathol Microbiol</source><year>2020</year><volume>63</volume><issue>1</issue><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.4103/IJPM.IJPM_403_19</pub-id><?supplied-pmid 32031123?><pub-id pub-id-type="pmid">32031123</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karanian-Philippe</surname><given-names>M</given-names></name><name><surname>Velasco</surname><given-names>V</given-names></name><name><surname>Longy</surname><given-names>M</given-names></name><name><surname>Floquet</surname><given-names>A</given-names></name><name><surname>Arnould</surname><given-names>L</given-names></name><name><surname>Coindre</surname><given-names>JM</given-names></name><name><surname>Le Naoures-Mear</surname><given-names>C</given-names></name><name><surname>Averous</surname><given-names>G</given-names></name><name><surname>Guyon</surname><given-names>F</given-names></name><name><surname>MacGrogan</surname><given-names>G</given-names></name><etal/></person-group><article-title>SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): a comprehensive analysis of 116 rare gynecologic tumors, 9 soft tissue tumors, and 9 melanomas</article-title><source>Am J Surg Pathol</source><year>2015</year><volume>39</volume><issue>9</issue><fpage>1197</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1097/PAS.0000000000000475</pub-id><?supplied-pmid 26135561?><pub-id pub-id-type="pmid">26135561</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>DC</given-names></name><name><surname>White</surname><given-names>YA</given-names></name><name><surname>Dau</surname><given-names>C</given-names></name><name><surname>Johnson</surname><given-names>AL</given-names></name></person-group><article-title>TLR4 activates NF-kappaB in human ovarian granulosa tumor cells</article-title><source>Biochem Biophys Res Commun</source><year>2011</year><volume>409</volume><issue>4</issue><fpage>675</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2011.05.063</pub-id><?supplied-pmid 21616060?><pub-id pub-id-type="pmid">21616060</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>XB</given-names></name><name><surname>Jimenez</surname><given-names>M</given-names></name><name><surname>Desai</surname><given-names>R</given-names></name><name><surname>Middleton</surname><given-names>LJ</given-names></name><name><surname>Joseph</surname><given-names>SR</given-names></name><name><surname>Ning</surname><given-names>G</given-names></name><name><surname>Allan</surname><given-names>CM</given-names></name><name><surname>Smith</surname><given-names>JT</given-names></name><name><surname>Handelsman</surname><given-names>DJ</given-names></name><name><surname>Walters</surname><given-names>KA</given-names></name></person-group><article-title>Characterizing the neuroendocrine and ovarian defects of androgen receptor-knockout female mice</article-title><source>Am J Physiol Endocrinol Metab</source><year>2013</year><volume>305</volume><issue>6</issue><fpage>E717</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00263.2013</pub-id><?supplied-pmid 23880317?><pub-id pub-id-type="pmid">23880317</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>JJ</given-names></name><name><surname>Cangemi</surname><given-names>NA</given-names></name><name><surname>Makker</surname><given-names>V</given-names></name><name><surname>Cadoo</surname><given-names>KA</given-names></name><name><surname>Liu</surname><given-names>JF</given-names></name><name><surname>Rasco</surname><given-names>DW</given-names></name><name><surname>Navarro</surname><given-names>WH</given-names></name><name><surname>Haqq</surname><given-names>CM</given-names></name><name><surname>Hyman</surname><given-names>DM</given-names></name></person-group><article-title>First-in-human phase I study of the activin a inhibitor, STM 434, in patients with granulosa cell ovarian cancer and other advanced solid tumors</article-title><source>Clin Cancer Res</source><year>2019</year><volume>25</volume><issue>18</issue><fpage>5458</fpage><lpage>5465</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-1065</pub-id><?supplied-pmid 31068369?><pub-id pub-id-type="pmid">31068369</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonilla</surname><given-names>L</given-names></name><name><surname>Oza</surname><given-names>AM</given-names></name></person-group><article-title>Targeting TGFbeta pathway in adult granulosa cell tumor: opening pandora's box?</article-title><source>Clin Cancer Res</source><year>2019</year><volume>25</volume><issue>18</issue><fpage>5432</fpage><lpage>5434</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-1605</pub-id><?supplied-pmid 31296528?><pub-id pub-id-type="pmid">31296528</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheen</surname><given-names>YY</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Park</surname><given-names>SA</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name><name><surname>Nam</surname><given-names>JS</given-names></name></person-group><article-title>Targeting the transforming growth factor-beta signaling in cancer therapy</article-title><source>Biomol Ther</source><year>2013</year><volume>21</volume><issue>5</issue><fpage>323</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.4062/biomolther.2013.072</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newsted</surname><given-names>D</given-names></name><name><surname>Banerjee</surname><given-names>S</given-names></name><name><surname>Watt</surname><given-names>K</given-names></name><name><surname>Nersesian</surname><given-names>S</given-names></name><name><surname>Truesdell</surname><given-names>P</given-names></name><name><surname>Blazer</surname><given-names>LL</given-names></name><name><surname>Cardarelli</surname><given-names>L</given-names></name><name><surname>Adams</surname><given-names>JJ</given-names></name><name><surname>Sidhu</surname><given-names>SS</given-names></name><name><surname>Craig</surname><given-names>AW</given-names></name></person-group><article-title>Blockade of TGF-beta signaling with novel synthetic antibodies limits immune exclusion and improves chemotherapy response in metastatic ovarian cancer models</article-title><source>Oncoimmunology</source><year>2019</year><volume>8</volume><issue>2</issue><fpage>e1539613</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2018.1539613</pub-id><?supplied-pmid 30713798?><pub-id pub-id-type="pmid">30713798</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Shan</surname><given-names>N</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Yi</surname><given-names>Z</given-names></name></person-group><article-title>LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells</article-title><source>Int J Clin Exp Pathol</source><year>2015</year><volume>8</volume><issue>5</issue><fpage>4923</fpage><lpage>4932</lpage><?supplied-pmid 26191185?><pub-id pub-id-type="pmid">26191185</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guerrero-Martinez</surname><given-names>JA</given-names></name><name><surname>Reyes</surname><given-names>JC</given-names></name></person-group><article-title>High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><issue>1</issue><fpage>2043</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-20217-3</pub-id><?supplied-pmid 29391527?><pub-id pub-id-type="pmid">29391527</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Madany</surname><given-names>P</given-names></name><name><surname>Dobson</surname><given-names>JR</given-names></name><name><surname>Schnabl</surname><given-names>JM</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>TC</given-names></name><name><surname>van Wijnen</surname><given-names>AJ</given-names></name><name><surname>Stein</surname><given-names>JL</given-names></name><name><surname>Lian</surname><given-names>JB</given-names></name><name><surname>Stein</surname><given-names>GS</given-names></name><etal/></person-group><article-title>The BRG1 chromatin remodeling enzyme links cancer cell metabolism and proliferation</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><issue>25</issue><fpage>38270</fpage><lpage>38281</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.9505</pub-id><?supplied-pmid 27223259?><pub-id pub-id-type="pmid">27223259</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname><given-names>Q</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>XH</given-names></name><name><surname>Le</surname><given-names>HV</given-names></name><name><surname>Massague</surname><given-names>J</given-names></name></person-group><article-title>Genome-wide impact of the BRG1 SWI/SNF chromatin remodeler on the transforming growth factor beta transcriptional program</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><issue>2</issue><fpage>1146</fpage><lpage>1155</lpage><pub-id pub-id-type="doi">10.1074/jbc.M707479200</pub-id><pub-id pub-id-type="pmid">18003620</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>ME</given-names></name><name><surname>Brunet</surname><given-names>A</given-names></name></person-group><article-title>FOXO transcription factors</article-title><source>Curr Biol</source><year>2007</year><volume>17</volume><issue>4</issue><fpage>R113</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2007.01.008</pub-id><?supplied-pmid 17307039?><pub-id pub-id-type="pmid">17307039</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massague</surname><given-names>J</given-names></name><name><surname>Seoane</surname><given-names>J</given-names></name><name><surname>Wotton</surname><given-names>D</given-names></name></person-group><article-title>Smad transcription factors</article-title><source>Genes Dev</source><year>2005</year><volume>19</volume><issue>23</issue><fpage>2783</fpage><lpage>2810</lpage><pub-id pub-id-type="doi">10.1101/gad.1350705</pub-id><?supplied-pmid 16322555?><pub-id pub-id-type="pmid">16322555</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name></person-group><article-title>FoxO1: a novel insight into its molecular mechanisms in the regulation of skeletal muscle differentiation and fiber type specification</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><issue>6</issue><fpage>10662</fpage><lpage>10674</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.12891</pub-id><?supplied-pmid 27793012?><pub-id pub-id-type="pmid">27793012</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>H</given-names></name><name><surname>Devalaraja</surname><given-names>S</given-names></name><name><surname>Chung</surname><given-names>ST</given-names></name><name><surname>Rane</surname><given-names>SG</given-names></name></person-group><article-title>TGF-beta1/Smad3 pathway targets PP2A-AMPK-FoxO1 signaling to regulate hepatic gluconeogenesis</article-title><source>J Biol Chem</source><year>2017</year><volume>292</volume><issue>8</issue><fpage>3420</fpage><lpage>3432</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.764910</pub-id><?supplied-pmid 28069811?><pub-id pub-id-type="pmid">28069811</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palazuelos</surname><given-names>J</given-names></name><name><surname>Klingener</surname><given-names>M</given-names></name><name><surname>Aguirre</surname><given-names>A</given-names></name></person-group><article-title>TGFbeta signaling regulates the timing of CNS myelination by modulating oligodendrocyte progenitor cell cycle exit through SMAD3/4/FoxO1/Sp1</article-title><source>J Neurosci</source><year>2014</year><volume>34</volume><issue>23</issue><fpage>7917</fpage><lpage>7930</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0363-14.2014</pub-id><?supplied-pmid 24899714?><pub-id pub-id-type="pmid">24899714</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>CH</given-names></name><name><surname>Skarra</surname><given-names>DV</given-names></name><name><surname>Rivera</surname><given-names>AJ</given-names></name><name><surname>Arriola</surname><given-names>DJ</given-names></name><name><surname>Thackray</surname><given-names>VG</given-names></name></person-group><article-title>Constitutively active FOXO1 diminishes activin induction of Fshb transcription in immortalized gonadotropes</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><issue>11</issue><fpage>e113839</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0113839</pub-id><?supplied-pmid 25423188?><pub-id pub-id-type="pmid">25423188</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armoni</surname><given-names>M</given-names></name><name><surname>Harel</surname><given-names>C</given-names></name><name><surname>Karni</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Bar-Yoseph</surname><given-names>F</given-names></name><name><surname>Ver</surname><given-names>MR</given-names></name><name><surname>Quon</surname><given-names>MJ</given-names></name><name><surname>Karnieli</surname><given-names>E</given-names></name></person-group><article-title>FOXO1 represses peroxisome proliferator-activated receptor-gamma1 and -gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><issue>29</issue><fpage>19881</fpage><lpage>19891</lpage><pub-id pub-id-type="doi">10.1074/jbc.M600320200</pub-id><?supplied-pmid 16670091?><pub-id pub-id-type="pmid">16670091</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedrick</surname><given-names>SM</given-names></name></person-group><article-title>The cunning little vixen: Foxo and the cycle of life and death</article-title><source>Nat Immunol</source><year>2009</year><volume>10</volume><issue>10</issue><fpage>1057</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1038/ni.1784</pub-id><?supplied-pmid 19701188?><pub-id pub-id-type="pmid">19701188</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>RJ</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name></person-group><article-title>Ras, PI(3)K and mTOR signalling controls tumour cell growth</article-title><source>Nature</source><year>2006</year><volume>441</volume><issue>7092</issue><fpage>424</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1038/nature04869</pub-id><?supplied-pmid 16724053?><pub-id pub-id-type="pmid">16724053</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fresno Vara</surname><given-names>JA</given-names></name><name><surname>Casado</surname><given-names>E</given-names></name><name><surname>de Castro</surname><given-names>J</given-names></name><name><surname>Cejas</surname><given-names>P</given-names></name><name><surname>Belda-Iniesta</surname><given-names>C</given-names></name><name><surname>Gonzalez-Baron</surname><given-names>M</given-names></name></person-group><article-title>PI3K/Akt signalling pathway and cancer</article-title><source>Cancer Treat Rev</source><year>2004</year><volume>30</volume><issue>2</issue><fpage>193</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2003.07.007</pub-id><pub-id pub-id-type="pmid">15023437</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Testa</surname><given-names>JR</given-names></name><name><surname>Tsichlis</surname><given-names>PN</given-names></name></person-group><article-title>AKT signaling in normal and malignant cells</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><issue>50</issue><fpage>7391</fpage><lpage>7393</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209100</pub-id><?supplied-pmid 16288285?><pub-id pub-id-type="pmid">16288285</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>N</given-names></name><name><surname>Hadden</surname><given-names>TJ</given-names></name><name><surname>Rishi</surname><given-names>AK</given-names></name></person-group><article-title>Akt, FoxO and regulation of apoptosis</article-title><source>Biochim Biophys Acta</source><year>2011</year><volume>1813</volume><issue>11</issue><fpage>1978</fpage><lpage>1986</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2011.03.010</pub-id><?supplied-pmid 21440011?><pub-id pub-id-type="pmid">21440011</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hornsveld</surname><given-names>M</given-names></name><name><surname>Dansen</surname><given-names>TB</given-names></name><name><surname>Derksen</surname><given-names>PW</given-names></name><name><surname>Burgering</surname><given-names>BMT</given-names></name></person-group><article-title>Re-evaluating the role of FOXOs in cancer</article-title><source>Semin Cancer Biol</source><year>2018</year><volume>50</volume><fpage>90</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2017.11.017</pub-id><?supplied-pmid 29175105?><pub-id pub-id-type="pmid">29175105</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hay</surname><given-names>N</given-names></name></person-group><article-title>Interplay between FOXO, TOR, and Akt</article-title><source>Biochim Biophys Acta</source><year>2011</year><volume>1813</volume><issue>11</issue><fpage>1965</fpage><lpage>1970</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2011.03.013</pub-id><?supplied-pmid 21440577?><pub-id pub-id-type="pmid">21440577</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>CW</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Karnes</surname><given-names>RJ</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name></person-group><article-title>AKT-phosphorylated FOXO1 suppresses ERK activation and chemoresistance by disrupting IQGAP1-MAPK interaction</article-title><source>EMBO J</source><year>2017</year><volume>36</volume><issue>8</issue><fpage>995</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.15252/embj.201695534</pub-id><?supplied-pmid 28279977?><pub-id pub-id-type="pmid">28279977</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloedjes</surname><given-names>TA</given-names></name><name><surname>de Wilde</surname><given-names>G</given-names></name><name><surname>Maas</surname><given-names>C</given-names></name><name><surname>Eldering</surname><given-names>E</given-names></name><name><surname>Bende</surname><given-names>RJ</given-names></name><name><surname>van Noesel</surname><given-names>CJM</given-names></name><name><surname>Pals</surname><given-names>ST</given-names></name><name><surname>Spaargaren</surname><given-names>M</given-names></name><name><surname>Guikema</surname><given-names>JEJ</given-names></name></person-group><article-title>AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma</article-title><source>Blood Adv</source><year>2020</year><volume>4</volume><issue>17</issue><fpage>4151</fpage><lpage>4164</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2019001393</pub-id><?supplied-pmid 32898245?><pub-id pub-id-type="pmid">32898245</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rassidakis</surname><given-names>GZ</given-names></name><name><surname>Feretzaki</surname><given-names>M</given-names></name><name><surname>Atwell</surname><given-names>C</given-names></name><name><surname>Grammatikakis</surname><given-names>I</given-names></name><name><surname>Lin</surname><given-names>Q</given-names></name><name><surname>Lai</surname><given-names>R</given-names></name><name><surname>Claret</surname><given-names>FX</given-names></name><name><surname>Medeiros</surname><given-names>LJ</given-names></name><name><surname>Amin</surname><given-names>HM</given-names></name></person-group><article-title>Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma</article-title><source>Blood</source><year>2005</year><volume>105</volume><issue>2</issue><fpage>827</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-06-2125</pub-id><?supplied-pmid 15374880?><pub-id pub-id-type="pmid">15374880</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fekete</surname><given-names>M</given-names></name><name><surname>Santiskulvong</surname><given-names>C</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Dorigo</surname><given-names>O</given-names></name></person-group><article-title>Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells</article-title><source>Anticancer Res</source><year>2012</year><volume>32</volume><issue>2</issue><fpage>445</fpage><lpage>452</lpage><?supplied-pmid 22287731?><pub-id pub-id-type="pmid">22287731</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cosimo</surname><given-names>E</given-names></name><name><surname>Tarafdar</surname><given-names>A</given-names></name><name><surname>Moles</surname><given-names>MW</given-names></name><name><surname>Holroyd</surname><given-names>AK</given-names></name><name><surname>Malik</surname><given-names>N</given-names></name><name><surname>Catherwood</surname><given-names>MA</given-names></name><name><surname>Hay</surname><given-names>J</given-names></name><name><surname>Dunn</surname><given-names>KM</given-names></name><name><surname>Macdonald</surname><given-names>AM</given-names></name><name><surname>Guichard</surname><given-names>SM</given-names></name><etal/></person-group><article-title>AKT/mTORC2 inhibition activates FOXO1 function in cll cells reducing B-Cell receptor-mediated survival</article-title><source>Clin Cancer Res</source><year>2019</year><volume>25</volume><issue>5</issue><fpage>1574</fpage><lpage>1587</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-2036</pub-id><?supplied-pmid 30559170?><pub-id pub-id-type="pmid">30559170</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name></person-group><article-title>FOXO1: a potential target for human diseases</article-title><source>Curr Drug Targets</source><year>2011</year><volume>12</volume><issue>9</issue><fpage>1235</fpage><lpage>1244</lpage><pub-id pub-id-type="doi">10.2174/138945011796150280</pub-id><?supplied-pmid 21443466?><pub-id pub-id-type="pmid">21443466</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloedjes</surname><given-names>TA</given-names></name><name><surname>de Wilde</surname><given-names>G</given-names></name><name><surname>Maas</surname><given-names>C</given-names></name><name><surname>Eldering</surname><given-names>EE</given-names></name><name><surname>Bende</surname><given-names>RJ</given-names></name><name><surname>van Noesel</surname><given-names>CJM</given-names></name><name><surname>Pals</surname><given-names>ST</given-names></name><name><surname>Spaargaren</surname><given-names>M</given-names></name><name><surname>Guikema</surname><given-names>JEJ</given-names></name></person-group><article-title>Targeting AKT elicits tumor suppressive functions of FOXO transcription factors and GSK3 kinase in Multiple Myeloma</article-title><source>bioRxiv</source><year>2019</year><volume>4</volume><fpage>816694</fpage></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>CG</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Ramachandran</surname><given-names>S</given-names></name><name><surname>Kaushik</surname><given-names>I</given-names></name><name><surname>Srivastava</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Srivastava</surname><given-names>SK</given-names></name></person-group><article-title>Role of Forkhead Box Class O proteins in cancer progression and metastasis</article-title><source>Semin Cancer Biol</source><year>2018</year><volume>50</volume><fpage>142</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2017.07.007</pub-id><?supplied-pmid 28774834?><pub-id pub-id-type="pmid">28774834</pub-id></element-citation></ref></ref-list></back></article>